(post-diagnosis low-dose aspirin,11.756876285817388)
(association post-diagnosis low-dose,7.054125771490433)
(type breast cancer,7.054125771490433)
(diagnose age year,7.054125771490433)
(her2 breast cancer,7.054125771490433)
(traumatic breast neuroma,7.054125771490433)
(high diagnostic accuracy,4.702750514326955)
(second third-degree relative,4.702750514326955)
(variation seroma production,4.702750514326955)
(aspirin risk cbc,4.702750514326955)
(breast cancer detection,4.702750514326955)
(breast lung cancer,4.702750514326955)
(prolactinoma higher family,4.702750514326955)
(subtype-specific prognostic signature,4.702750514326955)
(computer aid diagnosis,4.702750514326955)
(infrare fluorescent imaging,4.702750514326955)
(patient distant metastase,4.702750514326955)
(family history cancer,4.702750514326955)
(cancer family member,4.702750514326955)
(family member report,4.702750514326955)
(case traumatic breast,4.702750514326955)
(patient diagnose age,4.702750514326955)
(patient diagnose life,4.702750514326955)
(contralateral breast cancer,4.702750514326955)
(breast cancer survivor,4.702750514326955)
(cancer intake vitamin,4.702750514326955)
(intake vitamin derivative,4.702750514326955)
(multimodal contrast agent,4.702750514326955)
(cancer cell vitro,4.702750514326955)
(pet imaging patient,4.702750514326955)
(patient prolactinoma higher,4.702750514326955)
(cancer visually detectable,4.702750514326955)
(month completion radiotherapy,4.702750514326955)
(low-dose aspirin risk,4.702750514326955)
(observe variation seroma,4.702750514326955)
(locally-advanced breast cancer,4.702750514326955)
(summary hazard ratio,4.702750514326955)
(neuropathic breast pain,4.702750514326955)
(factor seroma production,4.702750514326955)
(dietary intake b-carotene,4.702750514326955)
(chest wall lesion,4.702750514326955)
(breast cancer intake,4.702750514326955)
(metastatic disease presentation,4.702750514326955)
(locoregional progression-free survival,4.702750514326955)
(cxcr4-directed pet imaging,4.702750514326955)
(abbreviated mri protocol,4.702750514326955)
(vitamin derivative breast,4.702750514326955)
(homologous recombination-mediated dna,4.702750514326955)
(assess diet diagnosis,4.702750514326955)
(cxcr4-targeted pet imaging,4.702750514326955)
(breast cancer receive,3.8918202981106265)
(primary breast cancer,3.316456153207065)
(patient breast cancer,3.316456153207065)
(breast cancer patient,2.505525936990736)
(damage follow platinum,2.3513752571634776)
(gene involve cancer,2.3513752571634776)
(shearlet transform image,2.3513752571634776)
(establish base glycosylation,2.3513752571634776)
(erbb family member,2.3513752571634776)
(intrauterine system-both finding,2.3513752571634776)
(barcode mode type,2.3513752571634776)
(probe 68ga-pentixafor result,2.3513752571634776)
(glycosylation membrane type,2.3513752571634776)
(compare semi-quantitatively comparison,2.3513752571634776)
(bromodomain extra-terminal protein,2.3513752571634776)
(additional indicator mutational,2.3513752571634776)
(breast cancer recognize,2.3513752571634776)
(anthracycline common agent,2.3513752571634776)
(positive family history,2.3513752571634776)
(examination concern gadolinium-based,2.3513752571634776)
(dynamic contrast-enhanced mri,2.3513752571634776)
(report increase risk,2.3513752571634776)
(imaging demonstrate selective,2.3513752571634776)
(atechnique aid radiologist,2.3513752571634776)
(cancer risk provide,2.3513752571634776)
(cancer barcode mode,2.3513752571634776)
(motivation perform breast,2.3513752571634776)
(extent duration breast,2.3513752571634776)
(imaging disease surveillance,2.3513752571634776)
(abbreviated mri exam,2.3513752571634776)
(prolactinoma breast lung,2.3513752571634776)
(0.91 observe substantial,2.3513752571634776)
(syndrome ctn validate,2.3513752571634776)
(expression metastase recurrent,2.3513752571634776)
(worldwide year previous,2.3513752571634776)
(high suspicion require,2.3513752571634776)
(view personal cancer,2.3513752571634776)
(cancer patient serum,2.3513752571634776)
(administration osteopontin-750 probe,2.3513752571634776)
(cancer patient anti-her2,2.3513752571634776)
(evidence low ctn,2.3513752571634776)
(cell death trigger,2.3513752571634776)
(phase directionality shift,2.3513752571634776)
(plan at-risk woman,2.3513752571634776)
(marked reduction cost,2.3513752571634776)
(cancer diagnosis urgently,2.3513752571634776)
(image enhancement method,2.3513752571634776)
(cxcr4-targeted tracer accumulation,2.3513752571634776)
(clinical biomarker patient,2.3513752571634776)
(model result ten,2.3513752571634776)
(regulation aim study,2.3513752571634776)
(cohort patient pituitary,2.3513752571634776)
(reduction cost mri,2.3513752571634776)
(change decade advance,2.3513752571634776)
(breast cancer highly,2.3513752571634776)
(prognosis patient treat,2.3513752571634776)
(receive treatment anthracycline,2.3513752571634776)
(study investigate modality,2.3513752571634776)
(case invasive lobular,2.3513752571634776)
(utility breast cancer,2.3513752571634776)
(highly sensitive tumor-specific,2.3513752571634776)
(factor will aid,2.3513752571634776)
(year median bmi,2.3513752571634776)
(total cancer risk,2.3513752571634776)
(status contralateral breast,2.3513752571634776)
(cancer presentation relapse,2.3513752571634776)
(non-functioning pituitary adenoma,2.3513752571634776)
(formation measure wound,2.3513752571634776)
(intervention exclude seroma,2.3513752571634776)
(energy mammography compute,2.3513752571634776)
(vivo tumor imaging,2.3513752571634776)
(sensitive test breast,2.3513752571634776)
(patient worldwide discovery,2.3513752571634776)
(mri protocol utility,2.3513752571634776)
(higher family nfpa,2.3513752571634776)
(pathway component brca1,2.3513752571634776)
(cxcr4-targeted pet probe,2.3513752571634776)
(acquisition interpretation time,2.3513752571634776)
(analysis define time-varying,2.3513752571634776)
(grade molecular subtype,2.3513752571634776)
(representative gene-expression-based signature,2.3513752571634776)
(seroma production 82.5,2.3513752571634776)
(neuroma patient report,2.3513752571634776)
(summarize representative gene-expression-based,2.3513752571634776)
(osteopontin-based probe identify,2.3513752571634776)
(counseling consultation better,2.3513752571634776)
(demonstrate phantom imaging,2.3513752571634776)
(cxcr4 imaging study,2.3513752571634776)
(immune checkpoint inhibitory,2.3513752571634776)
(aid formulation effective,2.3513752571634776)
(cancer method retrospective,2.3513752571634776)
(delay radiotherapy patient,2.3513752571634776)
(proportional hazard regression,2.3513752571634776)
(low ctn level,2.3513752571634776)
(patient treat high,2.3513752571634776)
(population tnbc patient,2.3513752571634776)
(patient compare 68ga-pentixafor,2.3513752571634776)
(dose anthracycline combination,2.3513752571634776)
(heterogeneous disease variable,2.3513752571634776)
(risk current user,2.3513752571634776)
(diagnosis conclusion finding,2.3513752571634776)
(main evidence low,2.3513752571634776)
(disease primary breast,2.3513752571634776)
(external beam radiotherapy,2.3513752571634776)
(patient serum detect,2.3513752571634776)
(previous study require,2.3513752571634776)
(breast cancer feasible,2.3513752571634776)
(cell noteworthy strategy,2.3513752571634776)
(dual approach direct,2.3513752571634776)
(outcome estrogen receptor,2.3513752571634776)
(reserve management tumour-related,2.3513752571634776)
(dce-mri broader population,2.3513752571634776)
(image case compare,2.3513752571634776)
(serum membrane type,2.3513752571634776)
(nac iort explain,2.3513752571634776)
(cancer detection outperform,2.3513752571634776)
(vitamin derivative associate,2.3513752571634776)
(selective accumulation fluorescent,2.3513752571634776)
(predispose gene dna,2.3513752571634776)
(ulceration bleed improve,2.3513752571634776)
(gene investigate mutation,2.3513752571634776)
(invasive lobular carcinoma,2.3513752571634776)
(seek develop multimodal,2.3513752571634776)
(improve breast cancer,2.3513752571634776)
(altogether study confirm,2.3513752571634776)
(dose duration treatment,2.3513752571634776)
(strategy andor early,2.3513752571634776)
(diagnosis year median,2.3513752571634776)
(risk pursue preventive,2.3513752571634776)
(major role signaling,2.3513752571634776)
(cardiotoxicity require additional,2.3513752571634776)
(meta-regression analysis adjustment,2.3513752571634776)
(fluorescent dye serve,2.3513752571634776)
(recombination-mediated dna damage,2.3513752571634776)
(concurrently anthracycline elderly,2.3513752571634776)
(family impact woman,2.3513752571634776)
(diagnosis prognosis patient,2.3513752571634776)
(early detectionof breast,2.3513752571634776)
(demographic disease characteristic,2.3513752571634776)
(aim collect family,2.3513752571634776)
(increase risk current,2.3513752571634776)
(pathway component vegf,2.3513752571634776)
(cancer cooperative group,2.3513752571634776)
(detectable 68ga-pentixafor pet,2.3513752571634776)
(provide good response,2.3513752571634776)
(breast cancer cooperative,2.3513752571634776)
(measure wound drain,2.3513752571634776)
(68ga-pentixafor pet image,2.3513752571634776)
(feasible properly select,2.3513752571634776)
(osteopontin peptide infrare,2.3513752571634776)
(hospital ulm perform,2.3513752571634776)
(low-dose aspirin 0.91,2.3513752571634776)
(vitro osteopontin-750 accumulation,2.3513752571634776)
(accumulate dose duration,2.3513752571634776)
(near-infrared fluorophore silver,2.3513752571634776)
(management recurrent her2,2.3513752571634776)
(processing analysis image,2.3513752571634776)
(good negative predictive,2.3513752571634776)
(inhibition impair ability,2.3513752571634776)
(literature review yield,2.3513752571634776)
(ondata phase directionality,2.3513752571634776)
(cost concept fast,2.3513752571634776)
(patient non-functioning pituitary,2.3513752571634776)
(cancer diagnosis larger,2.3513752571634776)
(large cohort patient,2.3513752571634776)
(barrier difficulty allot,2.3513752571634776)
(microrna inhibitormimic immunotherapy-based,2.3513752571634776)
(scan time high,2.3513752571634776)
(liver fluorescence imaging,2.3513752571634776)
(respondent tend compare,2.3513752571634776)
(corresponding cohort result,2.3513752571634776)
(differential diagnosis patient,2.3513752571634776)
(lung cancer shared,2.3513752571634776)
(higher family patient,2.3513752571634776)
(technical efficacy stage,2.3513752571634776)
(cohort study breast,2.3513752571634776)
(base presence metastatic,2.3513752571634776)
(relate better outcome,2.3513752571634776)
(treatment conjugate osteopontin,2.3513752571634776)
(multi-scale shearlet transform,2.3513752571634776)
(andor regional lymph,2.3513752571634776)
(female patient worldwide,2.3513752571634776)
(radiation primary tumour,2.3513752571634776)
(prolonged recovery delay,2.3513752571634776)
(secondary confirmation signal,2.3513752571634776)
(history trastuzumab-induced severe,2.3513752571634776)
(high-resolution image development,2.3513752571634776)
(efficient techniqueus detection,2.3513752571634776)
(human early detectionof,2.3513752571634776)
(neuroma accurate tissue,2.3513752571634776)
(require additional anti-her2,2.3513752571634776)
(result prolonged recovery,2.3513752571634776)
(survival inconsistent conduct,2.3513752571634776)
(intake assess diet,2.3513752571634776)
(performance cxcr4-directed pet,2.3513752571634776)
(noteworthy strategy base,2.3513752571634776)
(osteopontin-750 probe accumulate,2.3513752571634776)
(coronary syndrome ctn,2.3513752571634776)
(profile patient survival,2.3513752571634776)
(breast cancer conservative,2.3513752571634776)
(develop moist desquamation,2.3513752571634776)
(recombination-mediated dna repair,2.3513752571634776)
(membrane type mass,2.3513752571634776)
(survival survival patient,2.3513752571634776)
(pet prognostic factor,2.3513752571634776)
(completion radiotherapy locoregional,2.3513752571634776)
(develop abbreviated mri,2.3513752571634776)
(develop cbc median,2.3513752571634776)
(negative family history,2.3513752571634776)
(acute coronary syndrome,2.3513752571634776)
(image development tool,2.3513752571634776)
(sibling diagnose breast,2.3513752571634776)
(inhibition induce brcaness,2.3513752571634776)
(analyze multi-omic profile,2.3513752571634776)
(increase risk small,2.3513752571634776)
(indicative benign lesion,2.3513752571634776)
(mri protocol feasible,2.3513752571634776)
(contrast injection study,2.3513752571634776)
(allot time medical,2.3513752571634776)
(cancer survivor serve,2.3513752571634776)
(levonorgestrel intrauterine system-both,2.3513752571634776)
(risk factor enable,2.3513752571634776)
(breast cancer survival,2.3513752571634776)
(immunotherapy-based approach develop,2.3513752571634776)
(chemotherapy remain anthracycline,2.3513752571634776)
(breast pain diagnostic,2.3513752571634776)
(breast axilla result,2.3513752571634776)
(examine radiologist result,2.3513752571634776)
(dose adjuvant transtuzumab,2.3513752571634776)
(adjusted cbc associate,2.3513752571634776)
(breastaxillary surgery intervention,2.3513752571634776)
(subcutaneous breast tumor,2.3513752571634776)
(result rapid resolution,2.3513752571634776)
(perform patient previous,2.3513752571634776)
(identification cardiotoxicity ctn,2.3513752571634776)
(error computer aid,2.3513752571634776)
(family history age,2.3513752571634776)
(protein directly regulate,2.3513752571634776)
(risk levonorgestrel intrauterine,2.3513752571634776)
(aion allow vivo,2.3513752571634776)
(disease unusual physical,2.3513752571634776)
(disease locoregional radiotherapy,2.3513752571634776)
(co-encapsulation near-infrared fluorophore,2.3513752571634776)
(history age onset,2.3513752571634776)
(result consistent previous,2.3513752571634776)
(call crispr-cas9-based gene,2.3513752571634776)
(carcinoma case invasive,2.3513752571634776)
(inception january 2018,2.3513752571634776)
(low-dose aspirin cbc,2.3513752571634776)
(primary undergo cxcr4-targeted,2.3513752571634776)
(evaluate vivo msot,2.3513752571634776)
(unknown primary undergo,2.3513752571634776)
(association prolactinoma family,2.3513752571634776)
(diagnostic performance cxcr4-directed,2.3513752571634776)
(allow vivo tumor,2.3513752571634776)
(pet image visually,2.3513752571634776)
(brca1 rad51 level,2.3513752571634776)
(receptor status contralateral,2.3513752571634776)
(mri protocol reflect,2.3513752571634776)
(hormonal contraception user,2.3513752571634776)
(imaging modality demonstrate,2.3513752571634776)
(strong evidence association,2.3513752571634776)
(identification evaluation cardiotoxicity,2.3513752571634776)
(evaluation cardiotoxicity monitoring,2.3513752571634776)
(induction epigenetic brcaness,2.3513752571634776)
(prospective study standardized,2.3513752571634776)
(underline necessity consider,2.3513752571634776)
(limit nontarget toxicity,2.3513752571634776)
(study association ctn,2.3513752571634776)
(cell vitro osteopontin-750,2.3513752571634776)
(imagesneed examine radiologist,2.3513752571634776)
(classifier conclusion multi-scale,2.3513752571634776)
(generate malign benign,2.3513752571634776)
(pathological prognostic factor,2.3513752571634776)
(compare patient diagnose,2.3513752571634776)
(consider latest treatment,2.3513752571634776)
(invasive disease fatal,2.3513752571634776)
(interview conduct purposively,2.3513752571634776)
(study wane time,2.3513752571634776)
(error visual fatigue.in,2.3513752571634776)
(lead cardiotoxicity appear,2.3513752571634776)
(brd4 pharmacological inhibition,2.3513752571634776)
(near-infrared fluorescence imaging,2.3513752571634776)
(policy maker focus,2.3513752571634776)
(prior surgery metastatic,2.3513752571634776)
(early diagnosis cardiotoxicity,2.3513752571634776)
(membrane type mannose,2.3513752571634776)
(rise healthcare expenditure,2.3513752571634776)
(breast cancer summary,2.3513752571634776)
(silver sulfide nanoparticle,2.3513752571634776)
(tumor site vitro,2.3513752571634776)
(image suitable algorithm,2.3513752571634776)
(difficulty allot time,2.3513752571634776)
(aim retrospective analysis,2.3513752571634776)
(imaging mammography digital,2.3513752571634776)
(conduct systemic review,2.3513752571634776)
(antibody small molecule,2.3513752571634776)
(uptake tumor-to-background ratio,2.3513752571634776)
(brd4 find involve,2.3513752571634776)
(better understanding tumour,2.3513752571634776)
(cancer recognize heterogeneous,2.3513752571634776)
(high specificity high,2.3513752571634776)
(contour enhancement image,2.3513752571634776)
(tend compare sister,2.3513752571634776)
(appear direct relationship,2.3513752571634776)
(responsible death united,2.3513752571634776)
(retrospective study ctn,2.3513752571634776)
(technique diffusion-weighted imaging,2.3513752571634776)
(imaging facilitate diagnosis,2.3513752571634776)
(twenty-six patient develop,2.3513752571634776)
(patient mastectomy patient,2.3513752571634776)
(difficult identify clearly,2.3513752571634776)
(diagnose early-onset breast,2.3513752571634776)
(require lesion small,2.3513752571634776)
(breast cancer complex,2.3513752571634776)
(prescription fill follow-up,2.3513752571634776)
(breast cancer overcome,2.3513752571634776)
(older strong family,2.3513752571634776)
(misdiagnosis human error,2.3513752571634776)
(cancer higher patient,2.3513752571634776)
(complex process involve,2.3513752571634776)
(gene-expression-based signature prognostic,2.3513752571634776)
(range imaging method,2.3513752571634776)
(association intake b-carotene,2.3513752571634776)
(genetic susceptibility prolactinoma,2.3513752571634776)
(contrast agent unenhanced,2.3513752571634776)
(cancer conservative treatment,2.3513752571634776)
(b-carotene breast cancer,2.3513752571634776)
(protocol utility breast,2.3513752571634776)
(molecular biology experiment,2.3513752571634776)
(signature originally design,2.3513752571634776)
(base glycosylation site,2.3513752571634776)
(future cxcr4 imaging,2.3513752571634776)
(study initial result,2.3513752571634776)
(petct image case,2.3513752571634776)
(tumour biology treatment,2.3513752571634776)
(transcript analyze thematic,2.3513752571634776)
(breast cancer current,2.3513752571634776)
(signature develop apply,2.3513752571634776)
(cross-sectional prospective retrospective,2.3513752571634776)
(patient negative family,2.3513752571634776)
(46.6 patient family,2.3513752571634776)
(harmless tissue neural,2.3513752571634776)
(long scan time,2.3513752571634776)
(adenoma acromegaly lung,2.3513752571634776)
(breast cancer personal,2.3513752571634776)
(signaling pathway involve,2.3513752571634776)
(severe reduction cardiac,2.3513752571634776)
(peptide infrare fluorescent,2.3513752571634776)
(contrast property improve,2.3513752571634776)
(associate 20-mcg ethinyl,2.3513752571634776)
(predict outcome estrogen,2.3513752571634776)
(novel target therapeutic,2.3513752571634776)
(evidence increase contrast,2.3513752571634776)
(therapy precision medicine,2.3513752571634776)
(cancer easily distinguish,2.3513752571634776)
(persistent low treat,2.3513752571634776)
(thematic analysis result,2.3513752571634776)
(self-examination clinical breast,2.3513752571634776)
(suvmax patient compare,2.3513752571634776)
(presentation tumour shrinkage,2.3513752571634776)
(fluorescent osteopontin target,2.3513752571634776)
(healthcare paradigm replace,2.3513752571634776)
(patient prolactinoma commonly,2.3513752571634776)
(expression determine immunohistochemistry,2.3513752571634776)
(result generate malign,2.3513752571634776)
(provide high-resolution image,2.3513752571634776)
(aspirin 0.91 observe,2.3513752571634776)
(cancer summary hazard,2.3513752571634776)
(correlation aforementioned prognostic,2.3513752571634776)
(diagnose life breast,2.3513752571634776)
(release profile aion,2.3513752571634776)
(breast cancer play,2.3513752571634776)
(pathway involve metastasis,2.3513752571634776)
(aim study assess,2.3513752571634776)
(inverse association prediagnosis,2.3513752571634776)
(patient cohort cxcr4-targeted,2.3513752571634776)
(wavelet filter help,2.3513752571634776)
(screening tool dual,2.3513752571634776)
(model limit nontarget,2.3513752571634776)
(result forty-three case,2.3513752571634776)
(improve detection breast,2.3513752571634776)
(relationship accumulate dose,2.3513752571634776)
(spite therapeutic benefit,2.3513752571634776)
(visually detectable 68ga-pentixafor,2.3513752571634776)
(invariance wavelet base,2.3513752571634776)
(tomosynthesis ultrasound long,2.3513752571634776)
(report imaging feature,2.3513752571634776)
(case include meta-analysis,2.3513752571634776)
(regard cancer causation,2.3513752571634776)
(report 15.3 patient,2.3513752571634776)
(adjuvant transtuzumab disease,2.3513752571634776)
(long noncoding rna,2.3513752571634776)
(ejection fraction receive,2.3513752571634776)
(68ga-pentixafor result thirteen,2.3513752571634776)
(fluorescence imaging investigate,2.3513752571634776)
(development target immune,2.3513752571634776)
(member report 15.3,2.3513752571634776)
(imaging study investigate,2.3513752571634776)
(despite trend radical,2.3513752571634776)
(diagnosis surveillance assessment,2.3513752571634776)
(signal nontarget organ,2.3513752571634776)
(cell overcome increase,2.3513752571634776)
(asymptomatic neuroma accurate,2.3513752571634776)
(involve metastasis aim,2.3513752571634776)
(find associate increase,2.3513752571634776)
(receptor human epidermal,2.3513752571634776)
(clinic year 2005-2017,2.3513752571634776)
(production extent duration,2.3513752571634776)
(oxide nanoparticle pegylate,2.3513752571634776)
(target immune cell,2.3513752571634776)
(examination mri continue,2.3513752571634776)
(breast cancer assume,2.3513752571634776)
(seroma production remain,2.3513752571634776)
(powerful technique call,2.3513752571634776)
(associate increase total,2.3513752571634776)
(axilla result total,2.3513752571634776)
(investigate woman currently,2.3513752571634776)
(systemnumber processing analysis,2.3513752571634776)
(prolactinoma young patient,2.3513752571634776)
(immunohistochemistry perform patient,2.3513752571634776)
(probe demonstrate bind,2.3513752571634776)
(acromegaly lung cancer,2.3513752571634776)
(user result consistent,2.3513752571634776)
(indicator mutational status,2.3513752571634776)
(gene editing emerge,2.3513752571634776)
(median follow-up month,2.3513752571634776)
(develop component include,2.3513752571634776)
(b-carotene woman breast,2.3513752571634776)
(vivo msot imaging,2.3513752571634776)
(combination trastuzumab identification,2.3513752571634776)
(couple possibility marked,2.3513752571634776)
(cancer systematically analyze,2.3513752571634776)
(family history female,2.3513752571634776)
(propose atechnique aid,2.3513752571634776)
(occur month complete,2.3513752571634776)
(network classifier conclusion,2.3513752571634776)
(cell bet inhibition,2.3513752571634776)
(prediction originally target,2.3513752571634776)
(treat high dose,2.3513752571634776)
(survivor provide strong,2.3513752571634776)
(disease choice anti-her2,2.3513752571634776)
(current development target,2.3513752571634776)
(process address issue,2.3513752571634776)
(colon cancer second,2.3513752571634776)
(intake b-carotene woman,2.3513752571634776)
(mechanism carcinogenesis clinical,2.3513752571634776)
(metastase recurrent breast,2.3513752571634776)
(cohort typical signature,2.3513752571634776)
(year previous decade,2.3513752571634776)
(breast imaging modality,2.3513752571634776)
(compare tumor signal,2.3513752571634776)
(understand filipino woman,2.3513752571634776)
(extra-terminal protein historically,2.3513752571634776)
(stratify base presence,2.3513752571634776)
(detection emerge role,2.3513752571634776)
(cancer notably collect,2.3513752571634776)
(25.6 kgm2 patient,2.3513752571634776)
(andor early detection,2.3513752571634776)
(management plan at-risk,2.3513752571634776)
(consistent previous study,2.3513752571634776)
(optoacoustic tomography selective,2.3513752571634776)
(metastase presentation conclusion,2.3513752571634776)
(wider population tnbc,2.3513752571634776)
(indicate subtype-specific prognostic,2.3513752571634776)
(2.5 post-injection signal,2.3513752571634776)
(study role palliative,2.3513752571634776)
(year disease control,2.3513752571634776)
(surgery number remove,2.3513752571634776)
(coefficient directional sensitive,2.3513752571634776)
(cardiac biomarker derive,2.3513752571634776)
(mass modified factor,2.3513752571634776)
(breast neuroma rare,2.3513752571634776)
(conclusion radiotherapy provide,2.3513752571634776)
(development tool promise,2.3513752571634776)
(20-mcg ethinyl estradiol,2.3513752571634776)
(alternative contrast-enhanced screening,2.3513752571634776)
(case underline necessity,2.3513752571634776)
(mannose receptor highly,2.3513752571634776)
(completion radiotherapy case,2.3513752571634776)
(examination screening mammography,2.3513752571634776)
(history malignancy diagnose,2.3513752571634776)
(aggressive course her2,2.3513752571634776)
(survival patient month,2.3513752571634776)
(production 82.5 multivariate,2.3513752571634776)
(treat 01.01.2010 31.12.2014,2.3513752571634776)
(patient positive family,2.3513752571634776)
(subtype 18f-fdg petct,2.3513752571634776)
(substantial variation accord,2.3513752571634776)
(association prediagnosis dietary,2.3513752571634776)
(monoclonal antibody small,2.3513752571634776)
(contrast agent non-ideal,2.3513752571634776)
(properly select case,2.3513752571634776)
(propose shearlet transform,2.3513752571634776)
(reson imaging 2018,2.3513752571634776)
(shift invariance wavelet,2.3513752571634776)
(brcaness brca1 wild-type,2.3513752571634776)
(production breast cancer,2.3513752571634776)
(necessity consider traumatic,2.3513752571634776)
(breast cancer numerous,2.3513752571634776)
(provide inconsistent result,2.3513752571634776)
(duration breast surgery,2.3513752571634776)
(systemic review meta-analysis,2.3513752571634776)
(generate brcaness phenotype,2.3513752571634776)
(find previous study,2.3513752571634776)
(tumor signal nontarget,2.3513752571634776)
(demonstrate selective accumulation,2.3513752571634776)
(effective multimodal contrast,2.3513752571634776)
(risk stratification lead,2.3513752571634776)
(search pubmed embase,2.3513752571634776)
(cancer change decade,2.3513752571634776)
(confidence interval association,2.3513752571634776)
(understanding factor will,2.3513752571634776)
(disease presentation patient,2.3513752571634776)
(increase contrast injection,2.3513752571634776)
(concern concurrently anthracycline,2.3513752571634776)
(independent prognostic factor,2.3513752571634776)
(confirm result vivo,2.3513752571634776)
(finances cancer risk,2.3513752571634776)
(pubmed embase perform,2.3513752571634776)
(positive breast cancer,2.3513752571634776)
(patient outcome cost,2.3513752571634776)
(multispectral optoacoustic tomography,2.3513752571634776)
(relapse disease unusual,2.3513752571634776)
(pituitary adenoma outpatient,2.3513752571634776)
(presence predispose gene,2.3513752571634776)
(neuroma rare benign,2.3513752571634776)
(study seek understand,2.3513752571634776)
(breast sensitive test,2.3513752571634776)
(control deterioration ejection,2.3513752571634776)
(amount observe variation,2.3513752571634776)
(previous breastaxillary surgery,2.3513752571634776)
(aid diagnosis systemnumber,2.3513752571634776)
(diagnosis family impact,2.3513752571634776)
(family member affect,2.3513752571634776)
(direct relationship accumulate,2.3513752571634776)
(increase total cancer,2.3513752571634776)
(nac median amount,2.3513752571634776)
(cardiovascular injury induce,2.3513752571634776)
(assess diagnostic performance,2.3513752571634776)
(0.70 highest versus,2.3513752571634776)
(contrast agent seek,2.3513752571634776)
(maintain high diagnostic,2.3513752571634776)
(accomplish x-ray mammography,2.3513752571634776)
(cardiotoxicity diagnosis prognosis,2.3513752571634776)
(method retrospective chart,2.3513752571634776)
(contrast agent breast,2.3513752571634776)
(datum discover membrane,2.3513752571634776)
(clearly distinguish subtype,2.3513752571634776)
(brd4 brca1rad51 expression,2.3513752571634776)
(trastuzumab-induced severe cardiotoxicity,2.3513752571634776)
(disease diagnosis clear,2.3513752571634776)
(high-dose radiotherapy unresected,2.3513752571634776)
(breast cancer describe,2.3513752571634776)
(patient history breast-conserving,2.3513752571634776)
(mode establish base,2.3513752571634776)
(82.5 multivariate analysis,2.3513752571634776)
(diagnosis implement computer,2.3513752571634776)
(cancer cxcr4-targeted tracer,2.3513752571634776)
(disease control deterioration,2.3513752571634776)
(diet diagnosis meta-regression,2.3513752571634776)
(specific population patient,2.3513752571634776)
(cancer vulnerability subjective,2.3513752571634776)
(imaging modality simplify,2.3513752571634776)
(seroma production extent,2.3513752571634776)
(diagnose earlier age,2.3513752571634776)
(chemokine receptor frequently,2.3513752571634776)
(strategy base drug,2.3513752571634776)
(intake b-carotene associate,2.3513752571634776)
(susceptibility prolactinoma breast,2.3513752571634776)
(thesuspicious region result,2.3513752571634776)
(rare case traumatic,2.3513752571634776)
(construct view personal,2.3513752571634776)
(pet find correlation,2.3513752571634776)
(high dose anthracycline,2.3513752571634776)
(inconsistent result occurrence,2.3513752571634776)
(aim overview abbreviated,2.3513752571634776)
(radiotherapy tumour shrinkage,2.3513752571634776)
(patient pituitary adenoma,2.3513752571634776)
(paradigm replace fee-for-service,2.3513752571634776)
(towavelet filter shearlet,2.3513752571634776)
(confidence interval estimate,2.3513752571634776)
(entity case report,2.3513752571634776)
(stage disease diagnosis,2.3513752571634776)
(random model result,2.3513752571634776)
(tnbc cell overcome,2.3513752571634776)
(imaging feature indicative,2.3513752571634776)
(continue promote quality,2.3513752571634776)
(pain high suspicion,2.3513752571634776)
(unresectable follow systemic,2.3513752571634776)
(shared genetic susceptibility,2.3513752571634776)
(investigate breast cancer,2.3513752571634776)
(agent detection breast,2.3513752571634776)
(higher suvmax patient,2.3513752571634776)
(prolactinoma commonly diagnose,2.3513752571634776)
(recurrent her2 breast,2.3513752571634776)
(68ga-pentixafor pet prognostic,2.3513752571634776)
(component include erbb,2.3513752571634776)
(month diagnosis month,2.3513752571634776)
(massive cell death,2.3513752571634776)
(normal human serum,2.3513752571634776)
(heterogeneous cancer female,2.3513752571634776)
(aion effective multimodal,2.3513752571634776)
(imaging technique require,2.3513752571634776)
(brca1 addition long,2.3513752571634776)
(cancer woman 12-15,2.3513752571634776)
(68ga-pentixafor maximum standardized,2.3513752571634776)
(screening woman increase,2.3513752571634776)
(functional breast imaging,2.3513752571634776)
(systemic therapy radiotherapy,2.3513752571634776)
(collect signature originally,2.3513752571634776)
(patient family member,2.3513752571634776)
(age year forty-two,2.3513752571634776)
(imaging 68ga-pentixafor maximum,2.3513752571634776)
(promise advanced diagnostic,2.3513752571634776)
(involve regulate gene,2.3513752571634776)
(gday increment intake,2.3513752571634776)
(seroma production type,2.3513752571634776)
(express breast cancer,2.3513752571634776)
(derive cardiac disease,2.3513752571634776)
(stage magn reson,2.3513752571634776)
(filter shearlet coefficient,2.3513752571634776)
(patient intrinsic subtype,2.3513752571634776)
(cancer better understanding,2.3513752571634776)
(biocompatibility aion form,2.3513752571634776)
(cancer assume membrane,2.3513752571634776)
(biomarker cardiotoxicity patient,2.3513752571634776)
(cancer unknown primary,2.3513752571634776)
(compute tomography magnetic,2.3513752571634776)
(platinum salt exposure,2.3513752571634776)
(signal intensity tumor,2.3513752571634776)
(negative her2 positive,2.3513752571634776)
(surgery rare clinical,2.3513752571634776)
(method comprehensive search,2.3513752571634776)
(prognosis assess diet,2.3513752571634776)
(membrane type distinguish,2.3513752571634776)
(bet inhibition impair,2.3513752571634776)
(advanced imaging examination,2.3513752571634776)
(mastectomy literature review,2.3513752571634776)
(base barcode mode,2.3513752571634776)
(model level evidence,2.3513752571634776)
(moist desquamation experience,2.3513752571634776)
(effective diagnosis treatment,2.3513752571634776)
(outcome record result,2.3513752571634776)
(techniqueus detection breast,2.3513752571634776)
(cancer highly sensitive,2.3513752571634776)
(bind breast cancer,2.3513752571634776)
(approach view current,2.3513752571634776)
(originally design predict,2.3513752571634776)
(excision definitive diagnosis,2.3513752571634776)
(breast cancer multispectral,2.3513752571634776)
(united states death,2.3513752571634776)
(lesion surgical excision,2.3513752571634776)
(focus curb advanced,2.3513752571634776)
(cancer survival inconsistent,2.3513752571634776)
(breast cancer barcode,2.3513752571634776)
(population article aim,2.3513752571634776)
(january 2018 summary,2.3513752571634776)
(contribute early diagnosis,2.3513752571634776)
(retrospective chart review,2.3513752571634776)
(cancer receive treatment,2.3513752571634776)
(breast surgery refractory,2.3513752571634776)
(dna damage follow,2.3513752571634776)
(recombination pathway inhibition,2.3513752571634776)
(risk associate 20-mcg,2.3513752571634776)
(mass spectrometry glycosylation,2.3513752571634776)
(radiotherapy provide good,2.3513752571634776)
(feasible tumor detectability,2.3513752571634776)
(trial practice study,2.3513752571634776)
(kgm2 patient mastectomy,2.3513752571634776)
(diagnosis treatment risk,2.3513752571634776)
(model examine association,2.3513752571634776)
(brca1 wild-type triple,2.3513752571634776)
(triple-negative breast cancer,2.3513752571634776)
(therapy patient history,2.3513752571634776)
(rare benign lesion,2.3513752571634776)
(dose-dependent reduction brca1,2.3513752571634776)
(relative patient report,2.3513752571634776)
(effective efficient techniqueus,2.3513752571634776)
(factor patient distant,2.3513752571634776)
(treatment option neoadjuvant,2.3513752571634776)
(better understanding factor,2.3513752571634776)
(definitive diagnosis rule,2.3513752571634776)
(metastatic disease locoregional,2.3513752571634776)
(associate improved breast,2.3513752571634776)
(intake b-carotene breast,2.3513752571634776)
(tool dual energy,2.3513752571634776)
(cost limit widespread,2.3513752571634776)
(screening behavior guide,2.3513752571634776)
(sample woman female,2.3513752571634776)
(promote quality appropriateness,2.3513752571634776)
(ctn routine clinical,2.3513752571634776)
(iort explain small,2.3513752571634776)
(copyright rights reserve,2.3513752571634776)
(inheritance locus control,2.3513752571634776)
(factor receptor status,2.3513752571634776)
(iron oxide nanoparticle,2.3513752571634776)
(routine clinical biomarker,2.3513752571634776)
(algorithm apply identify,2.3513752571634776)
(chart review conduct,2.3513752571634776)
(study aspirin breast,2.3513752571634776)
(conclusion study adoption,2.3513752571634776)
(dna damage regulation,2.3513752571634776)
(conduct purposively sample,2.3513752571634776)
(high cost limit,2.3513752571634776)
(imaging probe potent,2.3513752571634776)
(young patient strong,2.3513752571634776)
(target population breast,2.3513752571634776)
(study provide update,2.3513752571634776)
(inhibitor altogether study,2.3513752571634776)
(0.93 gday increment,2.3513752571634776)
(traumatic neuroma differential,2.3513752571634776)
(therapy radiotherapy tumour,2.3513752571634776)
(transform propose shearlet,2.3513752571634776)
(visually detectable case,2.3513752571634776)
(improve therapy precision,2.3513752571634776)
(detectionof breast cancer,2.3513752571634776)
(human serum membrane,2.3513752571634776)
(woman dense breast,2.3513752571634776)
(nationwide cohort study,2.3513752571634776)
(cancer cell-related component,2.3513752571634776)
(lapatinib combine capecitabine,2.3513752571634776)
(emerge role value-based,2.3513752571634776)
(investigate modality specific,2.3513752571634776)
(cancer introduce cxcr4-targeted,2.3513752571634776)
(small patient cohort,2.3513752571634776)
(radiotherapy breast chest,2.3513752571634776)
(belief regard cancer,2.3513752571634776)
(therapy surgery radiation,2.3513752571634776)
(treatment anthracycline study,2.3513752571634776)
(decade development improve,2.3513752571634776)
(currently contrast agent,2.3513752571634776)
(involve gene investigate,2.3513752571634776)
(specific subgroup validate,2.3513752571634776)
(cycle regulator dna,2.3513752571634776)
(contrast agent functional,2.3513752571634776)
(patient history transtuzumab-induced,2.3513752571634776)
(apoptosis cell cycle,2.3513752571634776)
(hazard ratio 0.70,2.3513752571634776)
(cancer woman improve,2.3513752571634776)
(enhancement image segmentation,2.3513752571634776)
(routinely implement screening,2.3513752571634776)
(agent non-ideal safety,2.3513752571634776)
(evidence inverse association,2.3513752571634776)
(fee-for-service model level,2.3513752571634776)
(diagnosis treatment breast,2.3513752571634776)
(differentially express type,2.3513752571634776)
(pain diagnostic evaluation,2.3513752571634776)
(month complete radiotherapy,2.3513752571634776)
(tumour remain unresectable,2.3513752571634776)
(conservative treatment feasible,2.3513752571634776)
(osteopontin target probe,2.3513752571634776)
(longer duration increase,2.3513752571634776)
(surveillance therapeutic model,2.3513752571634776)
(cell-related component develop,2.3513752571634776)
(screening diagnosis treatment,2.3513752571634776)
(median amount seroma,2.3513752571634776)
(earlier age patient,2.3513752571634776)
(result small patient,2.3513752571634776)
(combination pharmacological induction,2.3513752571634776)
(association ctn biomarker,2.3513752571634776)
(cancer genetic counseling,2.3513752571634776)
(method lead decrease,2.3513752571634776)
(notably collect signature,2.3513752571634776)
(combine parp inhibitor,2.3513752571634776)
(accumulation base result,2.3513752571634776)
(shrinkage prior surgery,2.3513752571634776)
(breast cancer accomplish,2.3513752571634776)
(fluorescent imaging triple,2.3513752571634776)
(cancer play major,2.3513752571634776)
(centre university hospital,2.3513752571634776)
(inquiry face-to-face semi-structured,2.3513752571634776)
(exist contrast agent,2.3513752571634776)
(fear lack finances,2.3513752571634776)
(breast cancer systematically,2.3513752571634776)
(unresected locally-advanced breast,2.3513752571634776)
(treat patient lapatinib,2.3513752571634776)
(increase risk levonorgestrel,2.3513752571634776)
(cardiotoxicity patient breast,2.3513752571634776)
(damage repair generate,2.3513752571634776)
(diagnostic sensitivity woman,2.3513752571634776)
(metastasis aim retrospective,2.3513752571634776)
(exposure lead massive,2.3513752571634776)
(interpretation time maintain,2.3513752571634776)
(recovery delay radiotherapy,2.3513752571634776)
(diagnostic accuracy effort,2.3513752571634776)
(sulfide nanoparticle iron,2.3513752571634776)
(rasmapk pathway component,2.3513752571634776)
(independent data set,2.3513752571634776)
(age diagnosis year,2.3513752571634776)
(express type breast,2.3513752571634776)
(treatment wider population,2.3513752571634776)
(include case invasive,2.3513752571634776)
(involve dna damage,2.3513752571634776)
(nude mouse liver,2.3513752571634776)
(unknown primary cancer,2.3513752571634776)
(patient specific subgroup,2.3513752571634776)
(therapeutic option monoclonal,2.3513752571634776)
(registry main analysis,2.3513752571634776)
(crispr-cas9-based gene editing,2.3513752571634776)
(possibility marked reduction,2.3513752571634776)
(limited evidence inverse,2.3513752571634776)
(diagnosis month completion,2.3513752571634776)
(experience breast cancer,2.3513752571634776)
(ejection fraction discuss,2.3513752571634776)
(clear extent apparent,2.3513752571634776)
(inhibitor microrna inhibitormimic,2.3513752571634776)
(sensitivity myocardial injury,2.3513752571634776)
(previous decade development,2.3513752571634776)
(value-based healthcare define,2.3513752571634776)
(death trigger synthetic,2.3513752571634776)
(screening study seek,2.3513752571634776)
(rate novel target,2.3513752571634776)
(role value-based healthcare,2.3513752571634776)
(x-ray mammography mammography,2.3513752571634776)
(extent apparent increase,2.3513752571634776)
(study indicate potential,2.3513752571634776)
(indicate potential aion,2.3513752571634776)
(imaging evidence increase,2.3513752571634776)
(biomarker contribute early,2.3513752571634776)
(breast caner severe,2.3513752571634776)
(rule recurrent breast,2.3513752571634776)
(early detection screening,2.3513752571634776)
(serum detect normal,2.3513752571634776)
(highest versus lowest,2.3513752571634776)
(neoadjuvant systemic therapy,2.3513752571634776)
(result reveal respondent,2.3513752571634776)
(negligible cytotoxicity agreement,2.3513752571634776)
(behavior factor address,2.3513752571634776)
(analyze glycosylation membrane,2.3513752571634776)
(study cardiotoxicity diagnosis,2.3513752571634776)
(replace fee-for-service model,2.3513752571634776)
(locus control sister,2.3513752571634776)
(meta-analysis summarize result,2.3513752571634776)
(biomarker derive cardiac,2.3513752571634776)
(cohort cxcr4-targeted pet,2.3513752571634776)
(woman develop cbc,2.3513752571634776)
(characteristic treatment outcome,2.3513752571634776)
(expression confirm tnbc,2.3513752571634776)
(cancer study aim,2.3513752571634776)
(tumor triple-negative breast,2.3513752571634776)
(modality demonstrate phantom,2.3513752571634776)
(cancer receive external,2.3513752571634776)
(study standardized imaging,2.3513752571634776)
(minimal silver ion,2.3513752571634776)
(patient woman develop,2.3513752571634776)
(presentation relapse disease,2.3513752571634776)
(cancer causation personalistic,2.3513752571634776)
(aion negligible cytotoxicity,2.3513752571634776)
(stratification lead improve,2.3513752571634776)
(finding limited evidence,2.3513752571634776)
(metastasis unknown primary,2.3513752571634776)
(e.g. therapeutic approach,2.3513752571634776)
(meta-analysis dietary intake,2.3513752571634776)
(estradiol pill find,2.3513752571634776)
(prognostic separately assess,2.3513752571634776)
(latest treatment option,2.3513752571634776)
(multiresolution result generate,2.3513752571634776)
(background management locally-advanced,2.3513752571634776)
(cancer case include,2.3513752571634776)
(vivo provide high-resolution,2.3513752571634776)
(small advance timing,2.3513752571634776)
(bet protein directly,2.3513752571634776)
(cell cycle regulator,2.3513752571634776)
(pursue preventive strategy,2.3513752571634776)
(salt exposure lead,2.3513752571634776)
(neural network classifier,2.3513752571634776)
(review conduct patient,2.3513752571634776)
(choice anti-her2 therapy,2.3513752571634776)
(surgery length surgery,2.3513752571634776)
(thirteen patient diagnosis,2.3513752571634776)
(axillary lymph node,2.3513752571634776)
(age patient negative,2.3513752571634776)
(survival material method,2.3513752571634776)
(signature prognostic separately,2.3513752571634776)
(result total patient,2.3513752571634776)
(clinical entity case,2.3513752571634776)
(lesion persistent low,2.3513752571634776)
(originally target population,2.3513752571634776)
(require investigation breast,2.3513752571634776)
(cancer prognosis number,2.3513752571634776)
(familial cancer clustering,2.3513752571634776)
(woman 12-15 tumor,2.3513752571634776)
(discuss management recurrent,2.3513752571634776)
(include estrogen receptor,2.3513752571634776)
(tumor lesion measure,2.3513752571634776)
(safety issue imaging,2.3513752571634776)
(analyze cross-sectional prospective,2.3513752571634776)
(process involve gene,2.3513752571634776)
(imaging near-infrared fluorescence,2.3513752571634776)
(signature prognostic prediction,2.3513752571634776)
(adenoma outpatient clinic,2.3513752571634776)
(diagnosis clear extent,2.3513752571634776)
(cancer complex heterogeneous,2.3513752571634776)
(severe cardiotoxicity require,2.3513752571634776)
(efficacy stage magn,2.3513752571634776)
(reveal observe variation,2.3513752571634776)
(systemic therapy surgery,2.3513752571634776)
(assess ability prognosis,2.3513752571634776)
(background cxcr4 chemokine,2.3513752571634776)
(resonance imaging near-infrared,2.3513752571634776)
(treatment outcome record,2.3513752571634776)
(breast cancer treatment,2.3513752571634776)
(treatment breast cancer,2.3513752571634776)
(discuss review literature,2.3513752571634776)
(disease variable molecular,2.3513752571634776)
(advanced breast cancer,2.3513752571634776)
(identify thesuspicious region,2.3513752571634776)
(b-carotene associate improved,2.3513752571634776)
(follow-up 4.8 year,2.3513752571634776)
(anthracycline combination trastuzumab,2.3513752571634776)
(good response symptom,2.3513752571634776)
(mri nirf contrast,2.3513752571634776)
(risk screening behavior,2.3513752571634776)
(option method retrospective,2.3513752571634776)
(combine capecitabine result,2.3513752571634776)
(appropriateness imaging cornerstone,2.3513752571634776)
(stage iii breast,2.3513752571634776)
(main surgical side,2.3513752571634776)
(physical finding well,2.3513752571634776)
(prognosis prediction originally,2.3513752571634776)
(well history trastuzumab-induced,2.3513752571634776)
(perform breast self-examination,2.3513752571634776)
(one-year exposure lag,2.3513752571634776)
(tumor-specific imaging facilitate,2.3513752571634776)
(carcinogenesis clinical behavior,2.3513752571634776)
(personal cancer vulnerability,2.3513752571634776)
(median follow-up 4.8,2.3513752571634776)
(lead improve therapy,2.3513752571634776)
(ctn biomarker cardiotoxicity,2.3513752571634776)
(clinical breast examination,2.3513752571634776)
(node metastasis unknown,2.3513752571634776)
(control patient study,2.3513752571634776)
(risk shape belief,2.3513752571634776)
(parp inhibitor altogether,2.3513752571634776)
(bleed improve follow,2.3513752571634776)
(breast cancer case,2.3513752571634776)
(cbc risk breast,2.3513752571634776)
(member report 12.1,2.3513752571634776)
(fluorescent imaging osteopontin-based,2.3513752571634776)
(year compare patient,2.3513752571634776)
(result occurrence contralateral,2.3513752571634776)
(will aid formulation,2.3513752571634776)
(previous study study,2.3513752571634776)
(conjugate osteopontin peptide,2.3513752571634776)
(potential aion effective,2.3513752571634776)
(undetectable lesion include,2.3513752571634776)
(overexpress invasive breast,2.3513752571634776)
(refractory neuropathic breast,2.3513752571634776)
(post-injection signal intensity,2.3513752571634776)
(select case asymptomatic,2.3513752571634776)
(effort develop abbreviated,2.3513752571634776)
(feature extract utilize,2.3513752571634776)
(mutation brca1 presence,2.3513752571634776)
(adjustment body mass,2.3513752571634776)
(university hospital ulm,2.3513752571634776)
(develop treatment finally,2.3513752571634776)
(production type surgery,2.3513752571634776)
(cohort result indicate,2.3513752571634776)
(target probe tumor,2.3513752571634776)
(treatment method lead,2.3513752571634776)
(cancer diagnosis family,2.3513752571634776)
(iort patient receive,2.3513752571634776)
(cohort study report,2.3513752571634776)
(commonly diagnose age,2.3513752571634776)
(complete radiotherapy case,2.3513752571634776)
(current hormonal contraception,2.3513752571634776)
(gene dna damage,2.3513752571634776)
(exclude seroma formation,2.3513752571634776)
(cancer danish breast,2.3513752571634776)
(resolution risk stratification,2.3513752571634776)
(correlation suvmax 68ga-pentixafor,2.3513752571634776)
(type distinguish type,2.3513752571634776)
(deterioration ejection fraction,2.3513752571634776)
(biology treatment option,2.3513752571634776)
(detection outperform conventional,2.3513752571634776)
(affect cancer breast,2.3513752571634776)
(12-15 tumor triple-negative,2.3513752571634776)
(18f-fdg pet find,2.3513752571634776)
(barcode mode interestingly,2.3513752571634776)
(control sister cancer,2.3513752571634776)
(order avoid human,2.3513752571634776)
(cancer spite therapeutic,2.3513752571634776)
(cardiotoxicity appear direct,2.3513752571634776)
(discovery independent data,2.3513752571634776)
(issue imaging technique,2.3513752571634776)
(diagnostic imaging disease,2.3513752571634776)
(diagnosis range imaging,2.3513752571634776)
(identification prognostic risk,2.3513752571634776)
(characteristic treatment cbc,2.3513752571634776)
(history breast surgery,2.3513752571634776)
(breast cancer method,2.3513752571634776)
(cancer centre university,2.3513752571634776)
(result thirteen patient,2.3513752571634776)
(sensitive tumor-specific imaging,2.3513752571634776)
(disease surveillance therapeutic,2.3513752571634776)
(intake 0.93 gday,2.3513752571634776)
(multi-omic profile patient,2.3513752571634776)
(observe conclusion cxcr4-directed,2.3513752571634776)
(cancer feasible tumor,2.3513752571634776)
(shape belief regard,2.3513752571634776)
(life breast lung,2.3513752571634776)
(symptom review experience,2.3513752571634776)
(article aim overview,2.3513752571634776)
(case ulceration bleed,2.3513752571634776)
(breast cancer tnbc,2.3513752571634776)
(guide phenomenological approach,2.3513752571634776)
(breast cancer difficult,2.3513752571634776)
(variable molecular mechanism,2.3513752571634776)
(direct relationship brd4,2.3513752571634776)
(nfpa patient colorectal,2.3513752571634776)
(therapeutic benefit cardiotoxicity,2.3513752571634776)
(lung cancer human,2.3513752571634776)
(glycosylation site base,2.3513752571634776)
(ulm perform patient,2.3513752571634776)
(age year second,2.3513752571634776)
(healthcare define patient,2.3513752571634776)
(background association vitamin,2.3513752571634776)
(mode interestingly triple,2.3513752571634776)
(conventional imaging mammography,2.3513752571634776)
(prognostic signature higher,2.3513752571634776)
(cell brd4 pharmacological,2.3513752571634776)
(remain anthracycline common,2.3513752571634776)
(cancer second third-degree,2.3513752571634776)
(interestingly triple negative,2.3513752571634776)
(model calculate hazard,2.3513752571634776)
(data set confirm,2.3513752571634776)
(receive neoadjuvant anti-her2,2.3513752571634776)
(fast abbreviated mri,2.3513752571634776)
(large nationwide cohort,2.3513752571634776)
(aid radiologist diagnosis,2.3513752571634776)
(palliative radiotherapy patient,2.3513752571634776)
(accumulation evaluate vivo,2.3513752571634776)
(transtuzumab-induced cardiac dysfunction,2.3513752571634776)
(breast cancer presentation,2.3513752571634776)
(breast mri protocol,2.3513752571634776)
(case invasive carcinoma,2.3513752571634776)
(cancer determine multiple,2.3513752571634776)
(define time-varying post-diagnosis,2.3513752571634776)
(determine immunohistochemistry perform,2.3513752571634776)
(conclusion multi-scale shearlet,2.3513752571634776)
(component develop component,2.3513752571634776)
(conclusion large nationwide,2.3513752571634776)
(directionality shift invariance,2.3513752571634776)
(compare sister construct,2.3513752571634776)
(directly regulate homologous,2.3513752571634776)
(subtype breast cancer,2.3513752571634776)
(assess brd4 regulation,2.3513752571634776)
(diagnose serve motivation,2.3513752571634776)
(treatment cancer include,2.3513752571634776)
(cost mri examination,2.3513752571634776)
(lowest intake 0.93,2.3513752571634776)
(12.1 patient prolactinoma,2.3513752571634776)
(protocol introduce shorten,2.3513752571634776)
(multivariate analysis reveal,2.3513752571634776)
(genetic counseling consultation,2.3513752571634776)
(validate clinical study,2.3513752571634776)
(cell vitro intravenous,2.3513752571634776)
(numerous gene-expression-based prognostic,2.3513752571634776)
(involve cancer development,2.3513752571634776)
(msot secondary confirmation,2.3513752571634776)
(diagnostic tool imaging,2.3513752571634776)
(radiotherapy applicable case,2.3513752571634776)
(high sensitivity myocardial,2.3513752571634776)
(tumor patient characteristic,2.3513752571634776)
(burden experience breast,2.3513752571634776)
(typical signature prognostic,2.3513752571634776)
(breast neuroma patient,2.3513752571634776)
(patient primary recurrent,2.3513752571634776)
(validate clinical trial,2.3513752571634776)
(experiment datum discover,2.3513752571634776)
(hormone receptor her2,2.3513752571634776)
(trend radical surgical,2.3513752571634776)
(proliferation tumor grade,2.3513752571634776)
(concern gadolinium-based contrast,2.3513752571634776)
(tumour-related symptom review,2.3513752571634776)
(case metastatic disease,2.3513752571634776)
(transferable enable clinician,2.3513752571634776)
(accuracy effort develop,2.3513752571634776)
(cell immune checkpoint,2.3513752571634776)
(pet demonstrate higher,2.3513752571634776)
(lesion measure compare,2.3513752571634776)
(vitro vivo provide,2.3513752571634776)
(higher resolution risk,2.3513752571634776)
(repair generate brcaness,2.3513752571634776)
(pharmacological inhibition bet,2.3513752571634776)
(brca1 wild-type tnbc,2.3513752571634776)
(novel clinical strategy,2.3513752571634776)
(associate mutation brca1,2.3513752571634776)
(relapse year chest,2.3513752571634776)
(cardiac ejection fraction,2.3513752571634776)
(detectable case exhibit,2.3513752571634776)
(cardiotoxicity monitoring chemotherapy,2.3513752571634776)
(signature strong independent,2.3513752571634776)
(frequently overexpress invasive,2.3513752571634776)
(shorten image acquisition,2.3513752571634776)
(radiology rise healthcare,2.3513752571634776)
(prediagnosis dietary intake,2.3513752571634776)
(detectability lower compare,2.3513752571634776)
(anthracycline study association,2.3513752571634776)
(identify clearly distinguish,2.3513752571634776)
(broader population article,2.3513752571634776)
(mri technique diffusion-weighted,2.3513752571634776)
(formulation effective management,2.3513752571634776)
(assessment response treatment,2.3513752571634776)
(intrinsic subtype attempt,2.3513752571634776)
(signature computational framework,2.3513752571634776)
(diagnosis patient history,2.3513752571634776)
(metastase involve neoadjuvant,2.3513752571634776)
(regional lymph node,2.3513752571634776)
(surgical side result,2.3513752571634776)
(easily distinguish barcode,2.3513752571634776)
(cancer conclusion large,2.3513752571634776)
(31.12.2014 breast cancer,2.3513752571634776)
(precise tool target,2.3513752571634776)
(therapy change aggressive,2.3513752571634776)
(kidney liver fluorescence,2.3513752571634776)
(follow systemic therapy,2.3513752571634776)
(finding consistently find,2.3513752571634776)
(third-degree relative report,2.3513752571634776)
(consider traumatic neuroma,2.3513752571634776)
(contraception user result,2.3513752571634776)
(unusual physical finding,2.3513752571634776)
(imaging triple negative,2.3513752571634776)
(contribution radiology rise,2.3513752571634776)
(patient relapse her2,2.3513752571634776)
(improve screening diagnosis,2.3513752571634776)
(suitable algorithm method,2.3513752571634776)
(case twenty-six patient,2.3513752571634776)
(primary tumour remain,2.3513752571634776)
(vegf family member,2.3513752571634776)
(carcinoma special type,2.3513752571634776)
(value-based healthcare paradigm,2.3513752571634776)
(ability prognosis prediction,2.3513752571634776)
(measure compare pathological,2.3513752571634776)
(reproducibility study initial,2.3513752571634776)
(maximum standardized uptake,2.3513752571634776)
(association vitamin intake,2.3513752571634776)
(modality simplify diagnosis,2.3513752571634776)
(follow-up apply one-year,2.3513752571634776)
(diagnosis risk stratification,2.3513752571634776)
(calculate hazard ratio,2.3513752571634776)
(assume membrane type,2.3513752571634776)
(maker focus curb,2.3513752571634776)
(expression brd4 find,2.3513752571634776)
(decade advance screen,2.3513752571634776)
(survival discovery independent,2.3513752571634776)
(danish cohort study,2.3513752571634776)
(outpatient clinic year,2.3513752571634776)
(molecule inhibitor target,2.3513752571634776)
(dermatitis median locoregional,2.3513752571634776)
(contrast agent detection,2.3513752571634776)
(signal accumulation infrare,2.3513752571634776)
(2018 summary hazard,2.3513752571634776)
(filipino woman incorporate,2.3513752571634776)
(cancer numerous gene-expression-based,2.3513752571634776)
(15.3 patient prolactinoma,2.3513752571634776)
(subtype attempt identify,2.3513752571634776)
(incorporate experience live,2.3513752571634776)
(comparison cxcr4 expression,2.3513752571634776)
(urgently accord preliminary,2.3513752571634776)
(provide strong evidence,2.3513752571634776)
(lesion importantly patient,2.3513752571634776)
(record result forty-three,2.3513752571634776)
(generally reserve management,2.3513752571634776)
(increase dna damage,2.3513752571634776)
(noncoding rna inhibitor,2.3513752571634776)
(radiotherapy unresected locally-advanced,2.3513752571634776)
(drug model examine,2.3513752571634776)
(study adoption ctn,2.3513752571634776)
(breast cancer danish,2.3513752571634776)
(year forty-two percent,2.3513752571634776)
(option neoadjuvant chemotherapy,2.3513752571634776)
(cardiac disease diagnosis,2.3513752571634776)
(cox proportional hazard,2.3513752571634776)
(death worldwide year,2.3513752571634776)
(base transform propose,2.3513752571634776)
(special type hormone,2.3513752571634776)
(cancer detection emerge,2.3513752571634776)
(detail ondata phase,2.3513752571634776)
(cancer invasive disease,2.3513752571634776)
(preclinical phase crucial,2.3513752571634776)
(tumour shrinkage occur,2.3513752571634776)
(invasive breast cancer,2.3513752571634776)
(patient survival discovery,2.3513752571634776)
(algorithm method paper,2.3513752571634776)
(neoadjuvant chemotherapy intra-operative,2.3513752571634776)
(homologous recombination pathway,2.3513752571634776)
(view current development,2.3513752571634776)
(suvmax 68ga-pentixafor pet,2.3513752571634776)
(osteopontin-750 accumulation evaluate,2.3513752571634776)
(model identify preventive,2.3513752571634776)
(ctn level relate,2.3513752571634776)
(term hormonal contraception,2.3513752571634776)
(synthetic lethality combine,2.3513752571634776)
(biomarker patient breast,2.3513752571634776)
(evidence technical efficacy,2.3513752571634776)
(repair explore novel,2.3513752571634776)
(cancer describe multiple,2.3513752571634776)
(cancer current hormonal,2.3513752571634776)
(imaging protocol reproducibility,2.3513752571634776)
(sensitive wavelet filter,2.3513752571634776)
(distinguish barcode mode,2.3513752571634776)
(lymph node metastasis,2.3513752571634776)
(segmentation algorithm apply,2.3513752571634776)
(probe accumulate preferentially,2.3513752571634776)
(cancer chest wall,2.3513752571634776)
(mri protocol introduce,2.3513752571634776)
(apply one-year exposure,2.3513752571634776)
(distinguish subtype breast,2.3513752571634776)
(protect copyright rights,2.3513752571634776)
(increment intake assess,2.3513752571634776)
(precision medicine patient,2.3513752571634776)
(chest wall andor,2.3513752571634776)
(breast cancer change,2.3513752571634776)
(regulator dna repair,2.3513752571634776)
(wavelet base transform,2.3513752571634776)
(tumor-to-background ratio tumor,2.3513752571634776)
(apply identify thesuspicious,2.3513752571634776)
(invasive carcinoma special,2.3513752571634776)
(cancer clustering patient,2.3513752571634776)
(appealing high diagnostic,2.3513752571634776)
(inhibitor compound clinic,2.3513752571634776)
(patient history breast,2.3513752571634776)
(cornerstone value-based healthcare,2.3513752571634776)
(inconsistent conduct systemic,2.3513752571634776)
(specificity high sensitivity,2.3513752571634776)
(discover membrane type,2.3513752571634776)
(initial result abbreviated,2.3513752571634776)
(wall andor regional,2.3513752571634776)
(visual fatigue.in order,2.3513752571634776)
(mri breast sensitive,2.3513752571634776)
(imaging aion allow,2.3513752571634776)
(history transtuzumab-induced cardiac,2.3513752571634776)
(therapeutic model limit,2.3513752571634776)
(preliminary molecular biology,2.3513752571634776)
(mammography underutilize perceive,2.3513752571634776)
(capecitabine result rapid,2.3513752571634776)
(breast cancer visually,2.3513752571634776)
(breast cancer age,2.3513752571634776)
(management discuss review,2.3513752571634776)
(semi-quantitatively comparison cxcr4,2.3513752571634776)
(diagnostic accuracy couple,2.3513752571634776)
(clinical trial practice,2.3513752571634776)
(ten study breast,2.3513752571634776)
(treatment lead cardiotoxicity,2.3513752571634776)
(history female patient,2.3513752571634776)
(2005-2017 46.6 patient,2.3513752571634776)
(interval association post-diagnosis,2.3513752571634776)
(lack finances cancer,2.3513752571634776)
(historically involve regulate,2.3513752571634776)
(define patient outcome,2.3513752571634776)
(gene-expression-based prognostic signature,2.3513752571634776)
(application preventive strategy,2.3513752571634776)
(imaging vivo compare,2.3513752571634776)
(result familial cancer,2.3513752571634776)
(factor enable effective,2.3513752571634776)
(breast cancer risk,2.3513752571634776)
(overview abbreviated fast,2.3513752571634776)
(include erbb family,2.3513752571634776)
(benign lesion report,2.3513752571634776)
(lobular carcinoma case,2.3513752571634776)
(lesion small imaging,2.3513752571634776)
(finding well history,2.3513752571634776)
(immune cell immune,2.3513752571634776)
(advance screen early,2.3513752571634776)
(nanoparticle pegylate micelle,2.3513752571634776)
(confirm subtype-specific signature,2.3513752571634776)
(anti-her2 therapy change,2.3513752571634776)
(member affect cancer,2.3513752571634776)
(colorectal cancer relative,2.3513752571634776)
(female sibling diagnose,2.3513752571634776)
(radiotherapy locoregional progression-free,2.3513752571634776)
(troponin high specificity,2.3513752571634776)
(median bmi 25.6,2.3513752571634776)
(strategy analyze cross-sectional,2.3513752571634776)
(diagnosis meta-regression analysis,2.3513752571634776)
(four-month history intractable,2.3513752571634776)
(aspirin estrogen receptor,2.3513752571634776)
(relative cancer higher,2.3513752571634776)
(perceive barrier difficulty,2.3513752571634776)
(treatment finally novel,2.3513752571634776)
(inhibitors-based treatment wider,2.3513752571634776)
(multiple study wane,2.3513752571634776)
(clustering patient prolactinoma,2.3513752571634776)
(tumor bed kidney,2.3513752571634776)
(lung colon cancer,2.3513752571634776)
(time-varying post-diagnosis low-dose,2.3513752571634776)
(determine multiple factor,2.3513752571634776)
(occurrence contralateral breast,2.3513752571634776)
(lethality combine parp,2.3513752571634776)
(low-dose aspirin estrogen,2.3513752571634776)
(year second third-degree,2.3513752571634776)
(treatment feasible properly,2.3513752571634776)
(experience live sister,2.3513752571634776)
(personal cancer risk,2.3513752571634776)
(side result prolonged,2.3513752571634776)
(production remain main,2.3513752571634776)
(worldwide discovery biomarker,2.3513752571634776)
(hormonal contraception find,2.3513752571634776)
(accurate tissue sampling,2.3513752571634776)
(strong association prolactinoma,2.3513752571634776)
(breast cancer invasive,2.3513752571634776)
(primary cancer visually,2.3513752571634776)
(component brca1 addition,2.3513752571634776)
(suspicion require lesion,2.3513752571634776)
(type differentially express,2.3513752571634776)
(time greater tumor,2.3513752571634776)
(cell bet inhibitor,2.3513752571634776)
(suvmax 3.5 18f-fdg,2.3513752571634776)
(tissue sampling case,2.3513752571634776)
(accord pattern low-dose,2.3513752571634776)
(multiple factor patient,2.3513752571634776)
(inhibitormimic immunotherapy-based approach,2.3513752571634776)
(msot imaging demonstrate,2.3513752571634776)
(analysis result reveal,2.3513752571634776)
(mortality rate novel,2.3513752571634776)
(higher proportion patient,2.3513752571634776)
(dna repair pathway,2.3513752571634776)
(play major role,2.3513752571634776)
(life result familial,2.3513752571634776)
(cancercell small contour,2.3513752571634776)
(radiotherapy seroma production,2.3513752571634776)
(relationship brd4 brca1rad51,2.3513752571634776)
(study require investigation,2.3513752571634776)
(agreement minimal silver,2.3513752571634776)
(low diagnostic sensitivity,2.3513752571634776)
(survival survival material,2.3513752571634776)
(suitable general diagnostic,2.3513752571634776)
(patient discomfort aim,2.3513752571634776)
(applicable case twenty-six,2.3513752571634776)
(strategy combination pharmacological,2.3513752571634776)
(detect normal human,2.3513752571634776)
(cardiotoxicity major concern,2.3513752571634776)
(factor address cancer,2.3513752571634776)
(number remove lymph,2.3513752571634776)
(spectrometry glycosylation site,2.3513752571634776)
(duration increase risk,2.3513752571634776)
(personal perceive risk,2.3513752571634776)
(cancer patient woman,2.3513752571634776)
(distant metastase involve,2.3513752571634776)
(molecular subtype observe,2.3513752571634776)
(4.8 year adjusted,2.3513752571634776)
(predictive conclusion study,2.3513752571634776)
(comprehensive search pubmed,2.3513752571634776)
(neoadjuvant anti-her2 treatment,2.3513752571634776)
(exposure lag cox,2.3513752571634776)
(injury induce chemotherapy,2.3513752571634776)
(family member rasmapk,2.3513752571634776)
(shearlet coefficient directional,2.3513752571634776)
(tool target treatment,2.3513752571634776)
(benign classification accurate,2.3513752571634776)
(systematically analyze glycosylation,2.3513752571634776)
(breast cancer notably,2.3513752571634776)
(tumor nude mouse,2.3513752571634776)
(cancer patient treat,2.3513752571634776)
(exam appealing high,2.3513752571634776)
(breast lung colon,2.3513752571634776)
(patient month completion,2.3513752571634776)
(surgery consider latest,2.3513752571634776)
(preferentially subcutaneous breast,2.3513752571634776)
(68ga-pentixafor pet correlation,2.3513752571634776)
(biology experiment datum,2.3513752571634776)
(therapy receive neoadjuvant,2.3513752571634776)
(disease presentation tumour,2.3513752571634776)
(collect family history,2.3513752571634776)
(perform inception january,2.3513752571634776)
(subtype observe conclusion,2.3513752571634776)
(implement screening woman,2.3513752571634776)
(damage repair complex,2.3513752571634776)
(result alternative contrast-enhanced,2.3513752571634776)
(tnbc additional indicator,2.3513752571634776)
(yield case traumatic,2.3513752571634776)
(course her2 breast,2.3513752571634776)
(consistently find previous,2.3513752571634776)
(treatment option method,2.3513752571634776)
(age transcript analyze,2.3513752571634776)
(cancer accomplish x-ray,2.3513752571634776)
(positive patient breast,2.3513752571634776)
(signature higher resolution,2.3513752571634776)
(accumulate preferentially subcutaneous,2.3513752571634776)
(contrast-enhanced screening tool,2.3513752571634776)
(mri exam appealing,2.3513752571634776)
(case exhibit suvmax,2.3513752571634776)
(patient receive iort,2.3513752571634776)
(design predict outcome,2.3513752571634776)
(cancer patient recurrent,2.3513752571634776)
(liver 2.5 post-injection,2.3513752571634776)
(therapeutic approach view,2.3513752571634776)
(presence metastatic disease,2.3513752571634776)
(separately assess ability,2.3513752571634776)
(technique call crispr-cas9-based,2.3513752571634776)
(tomography magnetic resonance,2.3513752571634776)
(lymph node nac,2.3513752571634776)
(disease relapse year,2.3513752571634776)
(extract utilize classify,2.3513752571634776)
(phenomenological approach inquiry,2.3513752571634776)
(family history breast,2.3513752571634776)
(epigenetic brcaness brca1,2.3513752571634776)
(induce brcaness phenotype,2.3513752571634776)
(receive iort patient,2.3513752571634776)
(inhibitor target specific,2.3513752571634776)
(cancer development tnbc,2.3513752571634776)
(clinical trial article,2.3513752571634776)
(change aggressive course,2.3513752571634776)
(case compare semi-quantitatively,2.3513752571634776)
(healthcare policy maker,2.3513752571634776)
(result misdiagnosis human,2.3513752571634776)
(compare pathological prognostic,2.3513752571634776)
(observe substantial variation,2.3513752571634776)
(consultation fear lack,2.3513752571634776)
(bet inhibitor compound,2.3513752571634776)
(iii breast caner,2.3513752571634776)
(risk provide inconsistent,2.3513752571634776)
(injury diagnosis risk,2.3513752571634776)
(factor include estrogen,2.3513752571634776)
(sister diagnose early-onset,2.3513752571634776)
(accurate 93.45 utilize,2.3513752571634776)
(fluorophore silver sulfide,2.3513752571634776)
(breast self-examination clinical,2.3513752571634776)
(agent seek develop,2.3513752571634776)
(application e.g. therapeutic,2.3513752571634776)
(probe tumor site,2.3513752571634776)
(emerge precise tool,2.3513752571634776)
(receptor status proliferation,2.3513752571634776)
(compare 18f-fdg pet,2.3513752571634776)
(discomfort aim study,2.3513752571634776)
(cbc associate post-diagnosis,2.3513752571634776)
(response treatment conjugate,2.3513752571634776)
(cancer cohort typical,2.3513752571634776)
(brca1 presence predispose,2.3513752571634776)
(repair complex process,2.3513752571634776)
(imaging breast cancer,2.3513752571634776)
(fuckasdgahaaetk despite trend,2.3513752571634776)
(prognostic factor molecular,2.3513752571634776)
(osteopontin-based probe demonstrate,2.3513752571634776)
(detection screening study,2.3513752571634776)
(report type pa.,2.3513752571634776)
(early-onset breast cancer,2.3513752571634776)
(transform detail ondata,2.3513752571634776)
(cancer age transcript,2.3513752571634776)
(breast cancer introduce,2.3513752571634776)
(conclusion cxcr4-directed pet,2.3513752571634776)
(enhancement method towavelet,2.3513752571634776)
(ratio tumor lesion,2.3513752571634776)
(benefit cardiotoxicity major,2.3513752571634776)
(myocardial injury diagnosis,2.3513752571634776)
(infrare fluorescent dye,2.3513752571634776)
(patient year disease,2.3513752571634776)
(diagnosis apply early,2.3513752571634776)
(node nac iort,2.3513752571634776)
(approach direct relationship,2.3513752571634776)
(generate strong contrast,2.3513752571634776)
(family patient non-functioning,2.3513752571634776)
(avoid human error,2.3513752571634776)
(radiotherapy patient discomfort,2.3513752571634776)
(history breast-conserving surgery,2.3513752571634776)
(anti-her2 treatment stage,2.3513752571634776)
(method paper propose,2.3513752571634776)
(trial article protect,2.3513752571634776)
(reveal respondent tend,2.3513752571634776)
(inhibition bet inhibitor,2.3513752571634776)
(treatment cardiac biomarker,2.3513752571634776)
(literature traumatic breast,2.3513752571634776)
(perform patient primary,2.3513752571634776)
(component vegf family,2.3513752571634776)
(median age diagnosis,2.3513752571634776)
(dual energy mammography,2.3513752571634776)
(technique require contrast,2.3513752571634776)
(diagnosis larger prospective,2.3513752571634776)
(review meta-analysis summarize,2.3513752571634776)
(cancer female patient,2.3513752571634776)
(patient diagnosis breast,2.3513752571634776)
(history cancer large,2.3513752571634776)
(imaging osteopontin-based probe,2.3513752571634776)
(addition long noncoding,2.3513752571634776)
(malignancy diagnose earlier,2.3513752571634776)
(recurrent disease primary,2.3513752571634776)
(breast cancer breast,2.3513752571634776)
(background sentence fuckasdgahaaetk,2.3513752571634776)
(subtype-specific signature strong,2.3513752571634776)
(review yield case,2.3513752571634776)
(healthcare expenditure healthcare,2.3513752571634776)
(barcode mode establish,2.3513752571634776)
(type hormone receptor,2.3513752571634776)
(nontarget organ confirm,2.3513752571634776)
(receptor highly express,2.3513752571634776)
(parp inhibitors-based treatment,2.3513752571634776)
(identify study barcode,2.3513752571634776)
(seroma production breast,2.3513752571634776)
(diagnostic evaluation management,2.3513752571634776)
(tumor imaging evidence,2.3513752571634776)
(distant metastase presentation,2.3513752571634776)
(ability tnbc cell,2.3513752571634776)
(review literature traumatic,2.3513752571634776)
(relative report higher,2.3513752571634776)
(identify woman record,2.3513752571634776)
(regulation homologous recombination-mediated,2.3513752571634776)
(perceive risk screening,2.3513752571634776)
(patient develop moist,2.3513752571634776)
(property improve biocompatibility,2.3513752571634776)
(specific application e.g.,2.3513752571634776)
(protocol reflect increase,2.3513752571634776)
(woman responsible death,2.3513752571634776)
(pituitary adenoma acromegaly,2.3513752571634776)
(identify preventive drug,2.3513752571634776)
(clinical study cardiotoxicity,2.3513752571634776)
(confirm bet protein,2.3513752571634776)
(causation personalistic personal,2.3513752571634776)
(development improve screening,2.3513752571634776)
(type surgery length,2.3513752571634776)
(analysis adjustment body,2.3513752571634776)
(mutation gene involve,2.3513752571634776)
(imaging investigate breast,2.3513752571634776)
(cancer woman responsible,2.3513752571634776)
(unresected locally advanced,2.3513752571634776)
(issue exist contrast,2.3513752571634776)
(advanced diagnostic imaging,2.3513752571634776)
(states death worldwide,2.3513752571634776)
(case analyze 2016,2.3513752571634776)
(report mastectomy literature,2.3513752571634776)
(transtuzumab disease relapse,2.3513752571634776)
(rad51 level hinder,2.3513752571634776)
(long term hormonal,2.3513752571634776)
(standardized uptake tumor-to-background,2.3513752571634776)
(fatigue.in order avoid,2.3513752571634776)
(injection study indicate,2.3513752571634776)
(proportion patient diagnose,2.3513752571634776)
(woman female sibling,2.3513752571634776)
(aspirin breast cancer,2.3513752571634776)
(dye serve contrast,2.3513752571634776)
(find involve dna,2.3513752571634776)
(desquamation experience grade,2.3513752571634776)
(mri continue promote,2.3513752571634776)
(surgery intervention exclude,2.3513752571634776)
(cancer treatment lead,2.3513752571634776)
(receptor frequently overexpress,2.3513752571634776)
(history breast lung,2.3513752571634776)
(checkpoint inhibitory therapy,2.3513752571634776)
(personalistic personal theory,2.3513752571634776)
(require contrast agent,2.3513752571634776)
(benign lesion surgical,2.3513752571634776)
(risk stratification acute,2.3513752571634776)
(screening breast dce-mri,2.3513752571634776)
(underutilize perceive barrier,2.3513752571634776)
(level evidence technical,2.3513752571634776)
(associate post-diagnosis low-dose,2.3513752571634776)
(x-ray mammography low,2.3513752571634776)
(tumor grade molecular,2.3513752571634776)
(higher patient diagnose,2.3513752571634776)
(seroma production primary,2.3513752571634776)
(exhibit suvmax 3.5,2.3513752571634776)
(silver ion release,2.3513752571634776)
(fraction receive dose,2.3513752571634776)
(cancer future cxcr4,2.3513752571634776)
(forty-three case analyze,2.3513752571634776)
(tracer accumulation base,2.3513752571634776)
(human error visual,2.3513752571634776)
(ion release profile,2.3513752571634776)
(overcome increase dna,2.3513752571634776)
(cancer surgery rare,2.3513752571634776)
(history intractable neuropathic,2.3513752571634776)
(harmfulor harmless tissue,2.3513752571634776)
(novel powerful technique,2.3513752571634776)
(embase perform inception,2.3513752571634776)
(study confirm bet,2.3513752571634776)
(cardiotoxicity main evidence,2.3513752571634776)
(mammography low diagnostic,2.3513752571634776)
(strong independent prognostic,2.3513752571634776)
(induce dose-dependent reduction,2.3513752571634776)
(presentation patient demographic,2.3513752571634776)
(introduce cxcr4-targeted pet,2.3513752571634776)
(human rapidly transferable,2.3513752571634776)
(danish breast cancer,2.3513752571634776)
(follow-up month diagnosis,2.3513752571634776)
(cancer-specific survival survival,2.3513752571634776)
(breast cancer family,2.3513752571634776)
(remain unresectable follow,2.3513752571634776)
(base result small,2.3513752571634776)
(target treatment cancer,2.3513752571634776)
(importantly patient year,2.3513752571634776)
(inclusion criterion median,2.3513752571634776)
(mode type breast,2.3513752571634776)
(abbreviate dynamic contrast-enhanced,2.3513752571634776)
(report 12.1 patient,2.3513752571634776)
(impair ability tnbc,2.3513752571634776)
(breast cancer-specific survival,2.3513752571634776)
(imaging patient breast,2.3513752571634776)
(study aim collect,2.3513752571634776)
(radiotherapy generally reserve,2.3513752571634776)
(crucial application preventive,2.3513752571634776)
(practice study summarize,2.3513752571634776)
(overcome limitation abbreviate,2.3513752571634776)
(study summarize representative,2.3513752571634776)
(site base barcode,2.3513752571634776)
(biomarker breast cancer,2.3513752571634776)
(analysis image suitable,2.3513752571634776)
(patient colorectal cancer,2.3513752571634776)
(reflect increase scrutiny,2.3513752571634776)
(cancer shearlet transform,2.3513752571634776)
(image visually undetectable,2.3513752571634776)
(cancer cell bet,2.3513752571634776)
(wall lesion persistent,2.3513752571634776)
(undergo cxcr4-targeted pet,2.3513752571634776)
(age year compare,2.3513752571634776)
(radical surgical approach,2.3513752571634776)
(adoption ctn routine,2.3513752571634776)
(member rasmapk pathway,2.3513752571634776)
(tumor 9.7 time,2.3513752571634776)
(93.45 utilize ddsm,2.3513752571634776)
(curb advanced imaging,2.3513752571634776)
(currently routinely implement,2.3513752571634776)
(history cancer study,2.3513752571634776)
(cancer risk pursue,2.3513752571634776)
(rapidly transferable enable,2.3513752571634776)
(implement computer aid,2.3513752571634776)
(nationwide registry main,2.3513752571634776)
(diagnosis cardiotoxicity main,2.3513752571634776)
(prognostic risk factor,2.3513752571634776)
(increase scrutiny disproportionate,2.3513752571634776)
(study report risk,2.3513752571634776)
(examine association post-diagnosis,2.3513752571634776)
(patient recurrent disease,2.3513752571634776)
(anti-her2 therapy patient,2.3513752571634776)
(modality specific application,2.3513752571634776)
(patient treat 01.01.2010,2.3513752571634776)
(length surgery number,2.3513752571634776)
(risk malignancy older,2.3513752571634776)
(understanding tumour biology,2.3513752571634776)
(imaging patient primary,2.3513752571634776)
(risk cardiovascular injury,2.3513752571634776)
(trigger synthetic lethality,2.3513752571634776)
(decrease mortality rate,2.3513752571634776)
(woman currently contrast,2.3513752571634776)
(brd4 regulation homologous,2.3513752571634776)
(elderly patient relapse,2.3513752571634776)
(develop apply clinical,2.3513752571634776)
(result association dietary,2.3513752571634776)
(breast cancer centre,2.3513752571634776)
(mammography compute tomography,2.3513752571634776)
(diagnosis rule recurrent,2.3513752571634776)
(dna repair explore,2.3513752571634776)
(progesterone receptor human,2.3513752571634776)
(lymph node patient,2.3513752571634776)
(resolution chest wall,2.3513752571634776)
(tool imaging breast,2.3513752571634776)
(stratification acute coronary,2.3513752571634776)
(postmenopausal patient history,2.3513752571634776)
(mammography effective efficient,2.3513752571634776)
(screening mammography underutilize,2.3513752571634776)
(death united states,2.3513752571634776)
(derivative associate survival,2.3513752571634776)
(type mannose receptor,2.3513752571634776)
(result indicate subtype-specific,2.3513752571634776)
(report rare case,2.3513752571634776)
(prognostic factor breast,2.3513752571634776)
(prolactinoma family history,2.3513752571634776)
(group database 2012,2.3513752571634776)
(cancer tnbc associate,2.3513752571634776)
(demonstrate higher suvmax,2.3513752571634776)
(role palliative radiotherapy,2.3513752571634776)
(receive dose adjuvant,2.3513752571634776)
(ultrasound long scan,2.3513752571634776)
(evaluation management discuss,2.3513752571634776)
(pet imaging 68ga-pentixafor,2.3513752571634776)
(unenhanced mri technique,2.3513752571634776)
(prognostic signature develop,2.3513752571634776)
(flow cytometry infrare,2.3513752571634776)
(prognostic factor corresponding,2.3513752571634776)
(lead massive cell,2.3513752571634776)
(caner severe reduction,2.3513752571634776)
(tomography selective binding,2.3513752571634776)
(study report increase,2.3513752571634776)
(intake breast cancer,2.3513752571634776)
(breast cancer chest,2.3513752571634776)
(preventive strategy analyze,2.3513752571634776)
(distinguish type breast,2.3513752571634776)
(magnetic resonance imaging,2.3513752571634776)
(mri examination concern,2.3513752571634776)
(third-degree relative cancer,2.3513752571634776)
(aspirin prescription fill,2.3513752571634776)
(status family history,2.3513752571634776)
(phenotype brca1 wild-type,2.3513752571634776)
(seroma formation measure,2.3513752571634776)
(analysis assess diagnostic,2.3513752571634776)
(aspirin cbc risk,2.3513752571634776)
(form co-encapsulation near-infrared,2.3513752571634776)
(image segmentation algorithm,2.3513752571634776)
(forty-two percent patient,2.3513752571634776)
(tnbc patient specific,2.3513752571634776)
(consultation better understanding,2.3513752571634776)
(patient primary breast,2.3513752571634776)
(additional anti-her2 therapy,2.3513752571634776)
(report higher proportion,2.3513752571634776)
(development tnbc additional,2.3513752571634776)
(25-30 breast cancer,2.3513752571634776)
(pattern low-dose aspirin,2.3513752571634776)
(cardiotoxicity ctn preclinical,2.3513752571634776)
(breast examination screening,2.3513752571634776)
(production conclusion factor,2.3513752571634776)
(breast pain high,2.3513752571634776)
(subjective risk shape,2.3513752571634776)
(outcome good negative,2.3513752571634776)
(serve motivation perform,2.3513752571634776)
(member apoptosis cell,2.3513752571634776)
(retrospective analysis seroma,2.3513752571634776)
(breast cancer spite,2.3513752571634776)
(nirf contrast property,2.3513752571634776)
(diagnosis urgently accord,2.3513752571634776)
(nanoparticle multimodal imaging,2.3513752571634776)
(non-ideal safety issue,2.3513752571634776)
(vulnerability subjective risk,2.3513752571634776)
(approach develop treatment,2.3513752571634776)
(total patient meet,2.3513752571634776)
(level relate better,2.3513752571634776)
(radiologist diagnosis breast,2.3513752571634776)
(role signaling pathway,2.3513752571634776)
(drain place breast,2.3513752571634776)
(computational framework analyze,2.3513752571634776)
(patient meet inclusion,2.3513752571634776)
(ctn biomarker contribute,2.3513752571634776)
(all-in-one nanoparticle multimodal,2.3513752571634776)
(mouse liver 2.5,2.3513752571634776)
(wild-type triple negative,2.3513752571634776)
(wall lesion importantly,2.3513752571634776)
(neuroma postmenopausal patient,2.3513752571634776)
(improve biocompatibility aion,2.3513752571634776)
(risk cbc identify,2.3513752571634776)
(identify flow cytometry,2.3513752571634776)
(preventive strategy andor,2.3513752571634776)
(patient unresected locally,2.3513752571634776)
(ratio 0.70 highest,2.3513752571634776)
(cytotoxicity agreement minimal,2.3513752571634776)
(prediction specific population,2.3513752571634776)
(apply clinical trial,2.3513752571634776)
(family nfpa patient,2.3513752571634776)
(cbc nationwide registry,2.3513752571634776)
(medicine patient breast,2.3513752571634776)
(utilize classify mammographic,2.3513752571634776)
(major concern concurrently,2.3513752571634776)
(aim study provide,2.3513752571634776)
(transform image enhancement,2.3513752571634776)
(include meta-analysis dietary,2.3513752571634776)
(wall disease choice,2.3513752571634776)
(relapse her2 breast,2.3513752571634776)
(filter help detect,2.3513752571634776)
(low treat patient,2.3513752571634776)
(her2 expression metastase,2.3513752571634776)
(approach inquiry face-to-face,2.3513752571634776)
(duration treatment cardiac,2.3513752571634776)
(cbc median follow-up,2.3513752571634776)
(repair pathway component,2.3513752571634776)
(place breast axilla,2.3513752571634776)
(subgroup validate clinical,2.3513752571634776)
(surgery four-month history,2.3513752571634776)
(conduct patient unresected,2.3513752571634776)
(shrinkage occur month,2.3513752571634776)
(molecular mechanism carcinogenesis,2.3513752571634776)
(diagnosis process address,2.3513752571634776)
(study report stage,2.3513752571634776)
(recognize heterogeneous cancer,2.3513752571634776)
(hazard regression model,2.3513752571634776)
(18f-fdg pet demonstrate,2.3513752571634776)
(summarize result association,2.3513752571634776)
(find increase risk,2.3513752571634776)
(breast chest wall,2.3513752571634776)
(supplement vitamin derivative,2.3513752571634776)
(factor association intake,2.3513752571634776)
(diagnose breast cancer,2.3513752571634776)
(receptor her2 expression,2.3513752571634776)
(chemotherapy intra-operative radiotherapy,2.3513752571634776)
(accord preliminary molecular,2.3513752571634776)
(level hinder homologous,2.3513752571634776)
(disproportionate contribution radiology,2.3513752571634776)
(cancer large cohort,2.3513752571634776)
(preventive drug model,2.3513752571634776)
(prognostic factor include,2.3513752571634776)
(strong family history,2.3513752571634776)
(complex heterogeneous disease,2.3513752571634776)
(breast tomosynthesis ultrasound,2.3513752571634776)
(diagnosis study report,2.3513752571634776)
(population patient intrinsic,2.3513752571634776)
(cancer diagnose serve,2.3513752571634776)
(patient study role,2.3513752571634776)
(cancer diagnosis range,2.3513752571634776)
(abbreviated fast breast,2.3513752571634776)
(probe identify flow,2.3513752571634776)
(factor corresponding cohort,2.3513752571634776)
(conclusion factor seroma,2.3513752571634776)
(inhibitor induce dose-dependent,2.3513752571634776)
(review experience high-dose,2.3513752571634776)
(survivor serve high-risk,2.3513752571634776)
(rna inhibitor microrna,2.3513752571634776)
(woman breast cancer,2.3513752571634776)
(general diagnostic tool,2.3513752571634776)
(higher risk malignancy,2.3513752571634776)
(target specific cancer,2.3513752571634776)
(protocol reproducibility study,2.3513752571634776)
(18f-fdg petct image,2.3513752571634776)
(type pa. patient,2.3513752571634776)
(cxcr4 expression determine,2.3513752571634776)
(timing diagnosis study,2.3513752571634776)
(regulate homologous recombination,2.3513752571634776)
(patient prolactinoma young,2.3513752571634776)
(anthracycline elderly patient,2.3513752571634776)
(address issue exist,2.3513752571634776)
(locoregional radiotherapy generally,2.3513752571634776)
(protocol feasible offer,2.3513752571634776)
(patient characteristic treatment,2.3513752571634776)
(perform dual approach,2.3513752571634776)
(aion generate strong,2.3513752571634776)
(advance timing diagnosis,2.3513752571634776)
(time medical consultation,2.3513752571634776)
(management tumour-related symptom,2.3513752571634776)
(overexpress 25-30 breast,2.3513752571634776)
(wound drain place,2.3513752571634776)
(dense breast result,2.3513752571634776)
(lung cancer family,2.3513752571634776)
(estrogen receptor progesterone,2.3513752571634776)
(lead decrease mortality,2.3513752571634776)
(breast cancer future,2.3513752571634776)
(disease characteristic treatment,2.3513752571634776)
(paper propose atechnique,2.3513752571634776)
(lesion include case,2.3513752571634776)
(monitoring chemotherapy cardiac,2.3513752571634776)
(protein historically involve,2.3513752571634776)
(classification accurate 93.45,2.3513752571634776)
(small contour enhancement,2.3513752571634776)
(dietary supplement vitamin,2.3513752571634776)
(surgery metastatic disease,2.3513752571634776)
(material method comprehensive,2.3513752571634776)
(phenotype tnbc cell,2.3513752571634776)
(fatal disease lung,2.3513752571634776)
(update risk factor,2.3513752571634776)
(tnbc cell noteworthy,2.3513752571634776)
(drug tumor patient,2.3513752571634776)
(gadolinium-based contrast agent,2.3513752571634776)
(face-to-face semi-structured interview,2.3513752571634776)
(clinician exploit platinum,2.3513752571634776)
(identify newly identify,2.3513752571634776)
(involve neoadjuvant systemic,2.3513752571634776)
(tnbc cell bet,2.3513752571634776)
(early identification evaluation,2.3513752571634776)
(wane time long,2.3513752571634776)
(criterion median age,2.3513752571634776)
(vivo msot secondary,2.3513752571634776)
(mutational status family,2.3513752571634776)
(mammography digital breast,2.3513752571634776)
(breast cancer conclusion,2.3513752571634776)
(diagnose life result,2.3513752571634776)
(target therapeutic option,2.3513752571634776)
(tnbc cell brd4,2.3513752571634776)
(tumour shrinkage prior,2.3513752571634776)
(imaging cornerstone value-based,2.3513752571634776)
(patient axillary lymph,2.3513752571634776)
(fast breast mri,2.3513752571634776)
(analysis seroma production,2.3513752571634776)
(potent dem mri,2.3513752571634776)
(meet inclusion criterion,2.3513752571634776)
(live sister diagnose,2.3513752571634776)
(breast cancer cohort,2.3513752571634776)
(production primary breast,2.3513752571634776)
(neuroma differential diagnosis,2.3513752571634776)
(analyze 2016 median,2.3513752571634776)
(objective breast cancer,2.3513752571634776)
(people higher risk,2.3513752571634776)
(experience grade radiation,2.3513752571634776)
(patient lapatinib combine,2.3513752571634776)
(method towavelet filter,2.3513752571634776)
(help detect cancercell,2.3513752571634776)
(accumulation fluorescent osteopontin,2.3513752571634776)
(study assess brd4,2.3513752571634776)
(greater tumor bed,2.3513752571634776)
(describe multiple study,2.3513752571634776)
(intra-operative radiotherapy seroma,2.3513752571634776)
(report risk associate,2.3513752571634776)
(purposively sample woman,2.3513752571634776)
(factor breast cancer,2.3513752571634776)
(female patient prolactinoma,2.3513752571634776)
(expenditure healthcare policy,2.3513752571634776)
(better outcome good,2.3513752571634776)
(phase crucial application,2.3513752571634776)
(find correlation aforementioned,2.3513752571634776)
(estrogen receptor positive,2.3513752571634776)
(phantom imaging aion,2.3513752571634776)
(attempt identify subtype-specific,2.3513752571634776)
(newly identify study,2.3513752571634776)
(apply early identification,2.3513752571634776)
(specific cancer cell-related,2.3513752571634776)
(01.01.2010 31.12.2014 breast,2.3513752571634776)
(number imagesneed examine,2.3513752571634776)
(pet probe 68ga-pentixafor,2.3513752571634776)
(cancer relative patient,2.3513752571634776)
(her2 positive breast,2.3513752571634776)
(base drug human,2.3513752571634776)
(lesion report mastectomy,2.3513752571634776)
(pathway inhibition induce,2.3513752571634776)
(multimodal imaging probe,2.3513752571634776)
(case asymptomatic neuroma,2.3513752571634776)
(small molecule inhibitor,2.3513752571634776)
(behavior guide phenomenological,2.3513752571634776)
(editing emerge precise,2.3513752571634776)
(article protect copyright,2.3513752571634776)
(visually undetectable lesion,2.3513752571634776)
(follow radiotherapy applicable,2.3513752571634776)
(tissue neural network,2.3513752571634776)
(malign benign classification,2.3513752571634776)
(woman improve breast,2.3513752571634776)
(reduction brca1 rad51,2.3513752571634776)
(intravenous administration osteopontin-750,2.3513752571634776)
(cancer receive anthracycline,2.3513752571634776)
(tumor detectability lower,2.3513752571634776)
(surveillance assessment response,2.3513752571634776)
(factor molecular subtype,2.3513752571634776)
(prospective retrospective study,2.3513752571634776)
(finally novel powerful,2.3513752571634776)
(common agent breast,2.3513752571634776)
(enable effective diagnosis,2.3513752571634776)
(cancer human early,2.3513752571634776)
(derivative breast cancer,2.3513752571634776)
(profile aion generate,2.3513752571634776)
(chest wall disease,2.3513752571634776)
(breast cancer shearlet,2.3513752571634776)
(fill follow-up apply,2.3513752571634776)
(contrast agent novel,2.3513752571634776)
(exploit platinum salt,2.3513752571634776)
(trastuzumab identification cardiotoxicity,2.3513752571634776)
(induce chemotherapy remain,2.3513752571634776)
(patient stratify base,2.3513752571634776)
(grade radiation dermatitis,2.3513752571634776)
(presentation conclusion radiotherapy,2.3513752571634776)
(reduction cardiac ejection,2.3513752571634776)
(association dietary supplement,2.3513752571634776)
(hinder homologous recombination-mediated,2.3513752571634776)
(receive external beam,2.3513752571634776)
(primary recurrent breast,2.3513752571634776)
(surgical approach breast,2.3513752571634776)
(compare 68ga-pentixafor pet,2.3513752571634776)
(limit widespread currently,2.3513752571634776)
(modified factor association,2.3513752571634776)
(rare clinical entity,2.3513752571634776)
(patient receive nac,2.3513752571634776)
(ethinyl estradiol pill,2.3513752571634776)
(cxcr4 chemokine receptor,2.3513752571634776)
(progression-free survival patient,2.3513752571634776)
(theory inheritance locus,2.3513752571634776)
(receive anthracycline treatment,2.3513752571634776)
(retrospective analysis assess,2.3513752571634776)
(sister construct view,2.3513752571634776)
(analyze thematic analysis,2.3513752571634776)
(salt parp inhibitors-based,2.3513752571634776)
(diffusion-weighted imaging investigate,2.3513752571634776)
(micelle aion negligible,2.3513752571634776)
(agent novel all-in-one,2.3513752571634776)
(woman increase risk,2.3513752571634776)
(site identify newly,2.3513752571634776)
(improved breast cancer,2.3513752571634776)
(membrane type differentially,2.3513752571634776)
(amount seroma production,2.3513752571634776)
(high-risk model identify,2.3513752571634776)
(site vitro vivo,2.3513752571634776)
(confirm tnbc cell,2.3513752571634776)
(fluorescence imaging vivo,2.3513752571634776)
(aion form co-encapsulation,2.3513752571634776)
(early diagnosis treatment,2.3513752571634776)
(cancer multispectral optoacoustic,2.3513752571634776)
(time maintain high,2.3513752571634776)
(vitro intravenous administration,2.3513752571634776)
(concept fast abbreviated,2.3513752571634776)
(utilize ddsm database,2.3513752571634776)
(dem mri nirf,2.3513752571634776)
(breast cancer better,2.3513752571634776)
(family history malignancy,2.3513752571634776)
(observational study aspirin,2.3513752571634776)
(database 2012 drug,2.3513752571634776)
(variation accord pattern,2.3513752571634776)
(enable clinician exploit,2.3513752571634776)
(cardiac troponin high,2.3513752571634776)
(breast cancer easily,2.3513752571634776)
(pa. patient positive,2.3513752571634776)
(seek understand filipino,2.3513752571634776)
(conventional x-ray mammography,2.3513752571634776)
(intractable neuropathic breast,2.3513752571634776)
(vitamin intake breast,2.3513752571634776)
(receptor positive patient,2.3513752571634776)
(negative predictive conclusion,2.3513752571634776)
(breast cancer determine,2.3513752571634776)
(screening behavior factor,2.3513752571634776)
(outperform conventional imaging,2.3513752571634776)
(traumatic neuroma breast,2.3513752571634776)
(2016 median follow-up,2.3513752571634776)
(radiotherapy case ulceration,2.3513752571634776)
(cooperative group database,2.3513752571634776)
(mammographic image harmfulor,2.3513752571634776)
(patient strong association,2.3513752571634776)
(personal theory inheritance,2.3513752571634776)
(result feature extract,2.3513752571634776)
(ctn validate clinical,2.3513752571634776)
(pet imaging suitable,2.3513752571634776)
(identify subtype-specific prognostic,2.3513752571634776)
(offer screening breast,2.3513752571634776)
(binding osteopontin-based probe,2.3513752571634776)
(treatment cbc nationwide,2.3513752571634776)
(directional sensitive wavelet,2.3513752571634776)
(study barcode mode,2.3513752571634776)
(system-both finding consistently,2.3513752571634776)
(gene expression brd4,2.3513752571634776)
(aforementioned prognostic factor,2.3513752571634776)
(serve contrast agent,2.3513752571634776)
(median locoregional progression-free,2.3513752571634776)
(malignancy older strong,2.3513752571634776)
(estrogen receptor status,2.3513752571634776)
(regulate gene expression,2.3513752571634776)
(region result feature,2.3513752571634776)
(report stage disease,2.3513752571634776)
(cancer surgery consider,2.3513752571634776)
(outcome cost concept,2.3513752571634776)
(derivative breast cancer-specific,2.3513752571634776)
(mastectomy patient receive,2.3513752571634776)
(intensity tumor 9.7,2.3513752571634776)
(confirmation signal accumulation,2.3513752571634776)
(survival patient distant,2.3513752571634776)
(prognostic prediction specific,2.3513752571634776)
(study study report,2.3513752571634776)
(effective management plan,2.3513752571634776)
(woman perceive personal,2.3513752571634776)
(radiation dermatitis median,2.3513752571634776)
(imaging investigate woman,2.3513752571634776)
(semi-structured interview conduct,2.3513752571634776)
(clinical behavior identification,2.3513752571634776)
(status proliferation tumor,2.3513752571634776)
(beam radiotherapy breast,2.3513752571634776)
(brca1rad51 expression confirm,2.3513752571634776)
(experience high-dose radiotherapy,2.3513752571634776)
(bmi 25.6 kgm2,2.3513752571634776)
(chemotherapy cardiac troponin,2.3513752571634776)
(test breast cancer,2.3513752571634776)
(radiotherapy case metastatic,2.3513752571634776)
(magn reson imaging,2.3513752571634776)
(facilitate diagnosis surveillance,2.3513752571634776)
(explain small amount,2.3513752571634776)
(breast-conserving surgery four-month,2.3513752571634776)
(triple negative her2,2.3513752571634776)
(surgery radiation primary,2.3513752571634776)
(option monoclonal antibody,2.3513752571634776)
(family member apoptosis,2.3513752571634776)
(time long term,2.3513752571634776)
(investigate mutation gene,2.3513752571634776)
(bet inhibitor induce,2.3513752571634776)
(apparent increase risk,2.3513752571634776)
(factor receptor overexpress,2.3513752571634776)
(limitation abbreviate dynamic,2.3513752571634776)
(pet correlation suvmax,2.3513752571634776)
(pegylate micelle aion,2.3513752571634776)
(clinical strategy combination,2.3513752571634776)
(cancer survivor provide,2.3513752571634776)
(population breast cancer,2.3513752571634776)
(disease lung cancer,2.3513752571634776)
(risk factor seroma,2.3513752571634776)
(patient previous breastaxillary,2.3513752571634776)
(bed kidney liver,2.3513752571634776)
(imaging examination mri,2.3513752571634776)
(body mass modified,2.3513752571634776)
(investigation breast cancer,2.3513752571634776)
(risk small advance,2.3513752571634776)
(prognosis number imagesneed,2.3513752571634776)
(address cancer genetic,2.3513752571634776)
(clinic perform dual,2.3513752571634776)
(receptor progesterone receptor,2.3513752571634776)
(3.5 18f-fdg pet,2.3513752571634776)
(behavior identification prognostic,2.3513752571634776)
(cancer overcome limitation,2.3513752571634776)
(human error computer,2.3513752571634776)
(wild-type tnbc cell,2.3513752571634776)
(neuroma breast cancer,2.3513752571634776)
(agent functional breast,2.3513752571634776)
(glycosylation site identify,2.3513752571634776)
(year 2005-2017 46.6,2.3513752571634776)
(cancer shared genetic,2.3513752571634776)
(year adjusted cbc,2.3513752571634776)
(image harmfulor harmless,2.3513752571634776)
(feasible offer screening,2.3513752571634776)
(breast cancer cxcr4-targeted,2.3513752571634776)
(demonstrate bind breast,2.3513752571634776)
(patient demographic disease,2.3513752571634776)
(diet diagnosis conclusion,2.3513752571634776)
(evidence association post-diagnosis,2.3513752571634776)
(accumulation infrare fluorescent,2.3513752571634776)
(small amount observe,2.3513752571634776)
(year chest wall,2.3513752571634776)
(drug human rapidly,2.3513752571634776)
(diagnosis treatment method,2.3513752571634776)
(simplify diagnosis process,2.3513752571634776)
(management locally-advanced breast,2.3513752571634776)
(result vivo msot,2.3513752571634776)
(standardized imaging protocol,2.3513752571634776)
(imaging suitable general,2.3513752571634776)
(result ten study,2.3513752571634776)
(perception screening behavior,2.3513752571634776)
(develop multimodal contrast,2.3513752571634776)
(breast cancer woman,2.3513752571634776)
(rapid resolution chest,2.3513752571634776)
(digital breast tomosynthesis,2.3513752571634776)
(low-dose aspirin prescription,2.3513752571634776)
(transform multiresolution result,2.3513752571634776)
(vivo compare tumor,2.3513752571634776)
(analysis reveal observe,2.3513752571634776)
(diagnosis systemnumber processing,2.3513752571634776)
(seroma production conclusion,2.3513752571634776)
(platinum salt parp,2.3513752571634776)
(explore novel clinical,2.3513752571634776)
(widespread currently routinely,2.3513752571634776)
(nanoparticle iron oxide,2.3513752571634776)
(receptor overexpress 25-30,2.3513752571634776)
(breast tumor nude,2.3513752571634776)
(remove lymph node,2.3513752571634776)
(symptom control patient,2.3513752571634776)
(result abbreviated mri,2.3513752571634776)
(image acquisition interpretation,2.3513752571634776)
(serve high-risk model,2.3513752571634776)
(mammography mammography effective,2.3513752571634776)
(shearlet transform multiresolution,2.3513752571634776)
(type mass spectrometry,2.3513752571634776)
(progression-free survival survival,2.3513752571634776)
(receive nac median,2.3513752571634776)
(medical consultation fear,2.3513752571634776)
(lag cox proportional,2.3513752571634776)
(patient report imaging,2.3513752571634776)
(conclusion finding limited,2.3513752571634776)
(perceive personal cancer,2.3513752571634776)
(response symptom control,2.3513752571634776)
(accuracy couple possibility,2.3513752571634776)
(main analysis define,2.3513752571634776)
(prognostic signature computational,2.3513752571634776)
(set confirm subtype-specific,2.3513752571634776)
(breast neuroma postmenopausal,2.3513752571634776)
(impact woman perceive,2.3513752571634776)
(fraction discuss management,2.3513752571634776)
(quality appropriateness imaging,2.3513752571634776)
(interval estimate random,2.3513752571634776)
(cancer difficult identify,2.3513752571634776)
(remain main surgical,2.3513752571634776)
(surgical excision definitive,2.3513752571634776)
(2012 drug tumor,2.3513752571634776)
(risk perception screening,2.3513752571634776)
(disease fatal disease,2.3513752571634776)
(radiotherapy patient labc,2.3513752571634776)
(feature indicative benign,2.3513752571634776)
(cancer personal perceive,2.3513752571634776)
(strong contrast imaging,2.3513752571634776)
(cytometry infrare fluorescent,2.3513752571634776)
(aid diagnosis implement,2.3513752571634776)
(time high cost,2.3513752571634776)
(cancer risk perception,2.3513752571634776)
(highly express breast,2.3513752571634776)
(9.7 time greater,2.3513752571634776)
(molecular subtype 18f-fdg,2.3513752571634776)
(contraception find associate,2.3513752571634776)
(sensitivity woman dense,2.3513752571634776)
(introduce shorten image,2.3513752571634776)
(versus lowest intake,2.3513752571634776)
(method retrospective analysis,2.3513752571634776)
(case report rare,2.3513752571634776)
(patient anti-her2 therapy,2.3513752571634776)
(pharmacological induction epigenetic,2.3513752571634776)
(lower compare 18f-fdg,2.3513752571634776)
(sentence fuckasdgahaaetk despite,2.3513752571634776)
(study ctn biomarker,2.3513752571634776)
(disease diagnosis apply,2.3513752571634776)
(follow platinum salt,2.3513752571634776)
(surgery refractory neuropathic,2.3513752571634776)
(scrutiny disproportionate contribution,2.3513752571634776)
(organ confirm result,2.3513752571634776)
(discovery biomarker breast,2.3513752571634776)
(ctn preclinical phase,2.3513752571634776)
(tnbc associate mutation,2.3513752571634776)
(pill find increase,2.3513752571634776)
(treatment risk cardiovascular,2.3513752571634776)
(sister cancer diagnose,2.3513752571634776)
(woman incorporate experience,2.3513752571634776)
(user longer duration,2.3513752571634776)
(agent unenhanced mri,2.3513752571634776)
(percent patient diagnose,2.3513752571634776)
(tool promise advanced,2.3513752571634776)
(compound clinic perform,2.3513752571634776)
(breast cancer unknown,2.3513752571634776)
(cancer patient axillary,2.3513752571634776)
(regression model calculate,2.3513752571634776)
(current user longer,2.3513752571634776)
(breast result alternative,2.3513752571634776)
(probe potent dem,2.3513752571634776)
(treatment stage iii,2.3513752571634776)
(breast dce-mri broader,2.3513752571634776)
(brcaness phenotype brca1,2.3513752571634776)
(cancer prognosis assess,2.3513752571634776)
(record primary breast,2.3513752571634776)
(larger prospective study,2.3513752571634776)
(brcaness phenotype tnbc,2.3513752571634776)
(anti-her2 therapy receive,2.3513752571634776)
(estimate random model,2.3513752571634776)
(small imaging investigation,2.3513752571634776)
(locally advanced breast,2.3513752571634776)
(novel all-in-one nanoparticle,2.3513752571634776)
(cbc identify woman,2.3513752571634776)
(patient report type,2.3513752571634776)
(improve follow radiotherapy,2.3513752571634776)
(sampling case underline,2.3513752571634776)
(shearlet transform detail,2.3513752571634776)
(node patient stratify,2.3513752571634776)
(provide update risk,2.3513752571634776)
(contrast-enhanced mri protocol,2.3513752571634776)
(woman record primary,2.3513752571634776)
(detect cancercell small,2.3513752571634776)
(selective binding osteopontin-based,2.3513752571634776)
(screen early diagnosis,2.3513752571634776)
(contrast imaging modality,2.3513752571634776)
(radiologist result misdiagnosis,2.3513752571634776)
(framework analyze multi-omic,2.3513752571634776)
(hazard ratio confidence,1.9459101490553132)
(damage regulation aim,1.9459101490553132)
(cancer common cancer,1.9459101490553132)
(human epidermal growth,1.9459101490553132)
(negative breast cancer,1.9459101490553132)
(study breast cancer,1.9459101490553132)
(diagnosis breast cancer,1.9459101490553132)
(breast cancer prognosis,1.9459101490553132)
(agent breast cancer,1.9459101490553132)
(common cancer woman,1.9459101490553132)
(epidermal growth factor,1.9459101490553132)
(cancer breast cancer,1.9459101490553132)
(breast cancer common,1.9459101490553132)
(recurrent breast cancer,1.9459101490553132)
(breast cancer cell,1.9459101490553132)
(breast cancer surgery,1.9459101490553132)
(triple negative breast,1.9459101490553132)
(detection breast cancer,1.9459101490553132)
(dna damage repair,1.9459101490553132)
(ratio confidence interval,1.9459101490553132)
(classify mammographic image,1.9459101490553132)
(growth factor receptor,1.9459101490553132)
(approach breast cancer,1.9459101490553132)
(increase risk breast,1.9459101490553132)
(risk breast cancer,1.6582280766035324)
(breast cancer diagnosis,1.4350845252893227)
